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Many exercise testing protocols used in clinical settings have been developed for 
apparently healthy (AH) populations, but may be inappropriate for cancer survivors (CS) 
due to cancer and treatment-related toxicities.  The Rocky Mountain Cancer 
Rehabilitation Institute (RMCRI) developed a cancer specific treadmill protocol to 
specifically address this issue.  Purpose:  To assess the validity of the RMCRI multistage 
treadmill protocol.  Methods:  61 participants (45 CS, 16 AH controls) completed three 
different treadmill protocols, the Bruce (BTP) (for AH subjects), RMCRI without gas 
analysis (RWOGAP), and RMCRI with gas analysis (RGAP), to compare values of peak 
oxygen consumption (VO2peak).  Participants completed the trials one week apart in 
random order.  Obtained VO2peak values from RGAP were compared against estimated 
VO2peak from the same gas analysis (GA) test using the American College of Sports 
Medicine (ACSM) prediction equations (EVACSM).  VO2peak from RGAP was also 
compared to the estimated values of VO2peak achieved during the Bruce protocol.  
Finally, VO2peak from RGAP was compared against predicted VO2peak values obtained 
from RWOGAP.  Correlations were run between all protocols for each group.  Results:  
For AH participants, no significant differences were observed between any of the
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VO2peak protocol values (p > 0.05), and positive strong correlations occurred between 
all protocols (r > 0.8).  Among CS,VO2peak between RGAP and BTP were significantly 
different (p < 0.05).  No significant differences in VO2peak values occurred between 
RGAP and EVACSM (p > 0.05).  A positive strong correlation occurred between RGAP 
VO2peak and EVACSM (r = 0.90), and between VO2peak from the RGAP and 
RWOGAP (r = 0.81).  A moderate positive correlation was observed between VO2peak 
values from BTP and RGAP (r = 0.51).  CS group treadmill time was significantly 
greater on RWOGAP (12.6 ± 2.8 min) than RGAP (12.1 ± 2.8 min) (p < 0.05).  
Conclusion:  Our findings suggest that the Bruce protocol is not an appropriate protocol 
for CS.  GA equipment may also negatively affect treadmill performance as well.  The 
observed high correlations and validity between predicted and observed VO2peak values 
suggest that the RMCRI cancer-specific protocol is a valid method of determining 
VO2peak and should be considered as the standard VO2peak treadmill test for cancer 
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 Cancer can be characterized as a group of diseases exemplified by atypical 
cellular growth and development.  Currently, there are approximately 13.7 million 
Americans living with a history of cancer, and about 1,658,370 new cases of cancer are 
expected to be diagnosed in 2015 (American Cancer Society [ACS], 2015). Males have a 
greater risk of developing cancer, with slightly less than a 50% chance of being 
diagnosed; whereas females have a little more than a 33% chance of being diagnosed 
their lifetime (ACS, 2015).  Unfortunately, more than a half million Americans are 
expected to succumb to cancer this year.  Encouragingly, there are about 12 million 
cancer survivors (CS) in the United States and this number continues to grow every year 
(Schmitz et al., 2010).  The 5-year survival rate for cancers diagnosed between 2002 and 
2008 is now 68%, which has increased from the 49% survival rate observed between 
1975-1977 (ACS, 2015).  This may be a result of earlier detection and the advancement 
in cancer treatments. 
 Throughout the literature, it has been demonstrated among CS that physical 
activity performed before, during, and after treatment has been a substantial factor in the 
reported improvements in physiological and psychological factors such as increased 





increased flexibility, decreased fatigue, decreased depression, and increased quality of 
life (QOL) (Anderson et al., 2010; Groeneveldt et al., 2013; Jones, Eves, Haykowsky, 
Freeland, & Mackey, 2009; Schneider, Hsieh, Sprod, Carter, & Hayward, 2007a; 
Schneider, Hsieh, Sprod, Carter, & Hayward, 2007b).  Despite the observed positive 
benefits of exercise, only a small percentage of CS choose to exercise during their 
treatment (Murnane, Geary, & Milne, 2012).  Since the benefits of exercise on cancer 
recovery have become better understood, a greater number of CS are requesting 
information about rehabilitation services (Thorsen et al., 2011).  Cancer rehabilitation 
programs should aim to improve a cancer survivor’s functional ability as well as optimize 
psychological well-being through formal exercise programming.  Cardiovascular function 
is considered to be an excellent measure of overall physical fitness, and has been shown 
to decrease in CS as a result of cancer and cancer treatments (Doyle, Neugut, Jacobson, 
Grann, & Hershman, 2005; Smoot, Johnson, Duda, Krasnoff, & Dodd, 2012; Taylor et al. 
2010).  This decline in cardiovascular fitness may be attributed directly to treatments 
such as chemotherapy and radiation or may be the result of a decline in overall physical 
activity due to general deconditioning (Jones et al., 2009; Schneider et al., 2007b; 
Shapiro & Recht, 2001).  Exercise has been shown to increase cardiovascular fitness and 
predicted VO2max in a cancer population (Schneider et al., 2007b), and several studies 
have demonstrated that physical activity is a safe intervention for CS (Doyle et al., 2006; 
Nelson et al., 2007).   
 A VO2max test using gas analysis (GA) is considered to be the gold standard for 
cardiorespiratory fitness, but it requires experienced personnel, expensive equipment, and 





Baldwin, 2005; Kim, Kang, Smith, & Landers, 2006; Jones et al., 2011).  However, 
protocols for this type of test are generally aimed at apparently healthy (AH) populations. 
For example, CS in particular may not be able to push themselves to the point of 
exhaustion due to the high intensities and requirements of the test. Many facilities do not 
have access to the equipment and personnel necessary for a true VO2max test; in these 
instances, a VO2peak test may be used, which is defined as the highest level of oxygen 
consumption achieved during a graded treadmill test, regardless of whether maximum 
criteria are met (Heyward & Gibson, 2014; Jones et al., 2007; Kim et al., 2006).  These 
tests are generally shorter in duration than VO2max tests, require no special equipment, are 
less stressful, and predict a value that is nearly identical to VO2max (De Backer et al., 
2007).  In light of this information, a specifically tailored VO2peak treadmill protocol is 
greatly needed for special populations, such as CS, to garner reliable VO2peak values.  
 The Rocky Mountain Cancer Rehabilitation Institute (RMCRI) multi-stage 
treadmill protocol has been used to assess cardiovascular function in CS (Shackelford, 
Brown, Lalonde, Hydock, & Schneider, 2012).  Intensities and grades advance during 
this protocol at a more manageable and appropriate pace when compared to protocols 
designed for AH populations.  While this protocol theoretically allows clinicians to get a 
more accurate measure of VO2peak due to a greater tolerance by CS, this protocol has not 
yet been fully validated. Therefore, the purpose of this study is to investigate whether the 











Statement of Purpose 
 
The purpose of this study was to assess the validity of the RMCRI multi-stage 
treadmill protocol for a cancer-specific population against standard metabolic GA and the 
Bruce treadmill protocol.  
Research Hypotheses 
H1: Peak volume of oxygen consumption obtained from the RMCRI protocol using GA 
will not significantly differ from VO2peak calculated from the last completed stage of the 
GA test using the American College of Sports Medicine’s (ACSM) walking/running 
equations for either the CS or AH group. 
H2: Peak volume of oxygen consumption achieved from the Bruce protocol will be 
significantly lower from VO2peak obtained using the RMCRI protocol using GA for the 
CS.  No significant differences will occur in the AH group. 
H3: Peak volume of oxygen consumption values obtained from the RMCRI protocol 
using GA will not be significantly different than VO2peak  values obtained from a separate 
RMCRI protocol not using GA for either CS or AH group.  This will indicate that a 
respiration mask used during GA does not inhibit a participant’s performance on a 
treadmill. 
Significance of Study 
 
 Cardiovascular fitness is one of the best ways of determining an individual’s 
overall health (Brooks et al., 2005; Jones, Haykowsky, Joy, & Douglas, 2008).  Maximal 
aerobic capacity (VO2max) is the maximum amount of oxygen consumed during maximal 
work.  This value is the best objective measure of cardiovascular fitness and provides 





Gundersen, & Levine, 2006; Kim et al., 2006; Lakoski, Eves, Douglas, & Jones, 2012).  
To achieve a true VO2max, a metabolic cart and additional equipment are needed to ensure 
the participant reaches maximum value criterion (respiratory exchange ratio >1.15, a 
plateau in VO2 with an increase in exercise intensity, blood lactate exceeding 8 mmol·L
-1, 
and failure to increase heart rate with an increased intensity) (Hawkins et al., 2006; 
Heyward & Gibson, 2014).  However, metabolic carts are very expensive to obtain and 
require trained personnel to accurately conduct the testing.  Another disadvantage of a 
VO2max test using a metabolic cart is that it may be extremely uncomfortable for a client 
to perform due to the use of a face mask to measure respiration.  This often leads to 
distress in patients who have respiratory difficulties, are claustrophobic, or who are 
unable to continuously breathe through their mouths.   
Due to these disadvantages, VO2max tests are not always a viable option.  This 
becomes particularly true for CS who are suffering from cancer and cancer-related 
toxicities. VO2peak tests without a metabolic cart are often used in place of VO2max tests, in 
which the highest value of VO2 achieved during a test is recorded, regardless of whether 
maximum criterion are met (Jones et al., 2011; Kim et al., 2006; Maeder et al., 2010; Pina 
& Karalis, 1990).  It should be noted that most VO2peak tests utilize a metabolic cart.  
When a VO2max test using a metabolic cart is attempted but none of the maximum value 
criterion are met, it is also labeled a VO2peak test.  However, VO2peak tests that do not 
utilize a metabolic cart significantly reduces the equipment needs, trained personnel 
required, and subject discomfort, while still achieving a reliable measure of maximal 





There are many cardiorespiratory protocols that measure VO2peak, which include 
but are not limited to:  the Bruce treadmill protocol (BTP), the Balke treadmill protocol, 
and the modified BTP.  These protocols are designed to increase the intensity at a 
magnitude that is too difficult and rely on substantial increases in both speed and incline.  
These types of protocols are inappropriate for special populations due to the risk of injury 
and difficulty in completion (Stone, Lawlor, Nolan, & Kenny, 2011; Wampler et al., 
2007; Winters-Stone et al., 2011).   
For this reason, ergometry and cardiac specific protocols have been developed but 
also are not appropriate for the cancer population.  Ergometry protocols rely on upper or 
lower body musculature to perform work at a certain cadence as resistance is increased.  
Cancer survivors often experience weakness, severe fatigue, and/or cachexia limiting 
strength (Berger, Gerber, & Mayer, 2012; Das et al., 2011; Fearon, 2011; Hayes et al., 
2013; Schneider, Dennehy, Roozeboom, & Carter, 2002; Shapiro & Recht, 2001; Yeo et 
al., 2012).  Ergometry protocols are often terminated due to an inability to pedal, which 
represents muscular weakness and fatigue, not aerobic capacity.  Cardiac protocols such 
as the Naughton are less intense and progress more slowly than standard protocols, but 
often rely on an extended warm-up and long duration (Peel et al., 2009; Pina & Karalis, 
1990; Watchie et al., 1986).  Due to treatment-related toxicities, many CS experience 
debilitating fatigue which limits their ability to perform longer duration aerobic activity 
(Burnham & Wilcox, 2002).  Many patients are unable to sustain cardiovascular activities 
(such as walking) for the required warm-up duration or at the required initial speed, thus 





must be used to address the needs of CS, yet provide a reliable value of VO2peak.  The 
RMCRI treadmill protocol was created to address this need.  
 The RMCRI treadmill protocol increases speed and incline at a lower degree of 
intensity with shorter (one minute) stages, yet still yields an accurate VO2peak value 
(Shackelford et al., 2012).  The first stage and progression of the RMCRI protocol is 
manageable for patients with the severest of toxicities, starting at a speed of one mile per 
hour (mph) at a 0% incline, yet the total length of the protocol is long enough to allow the 
more fit patients to be measured.  This protocol utilizes a mode of progression that does 
not rely on maximal work rate until the later stages.  With the exception of the first initial 
increase in incline (+2.0%), the incline is never increased by more than 1.0% per minute 
and speed is increased by 0.1 mph per minute for the majority of the test.  The shorter 
stages allow patients to complete entire stages frequently, allowing clinicians to calculate 
VO2peak from the highest intensities sustained when fatigue is achieved.  Steady state heart 
rate may not be achieved due to the higher rate of increasing intensity. 
Due to the fact that there are no current cancer-specific treadmill protocols, CS 
must use AH or cardiac population treadmill protocols to determine their VO2peak.  Cancer 
survivors who are suffering from treatment-related toxicities and side-effects may not be 
able to fully exert themselves on these protocols due to the high intensities and durations 
required.  Without a valid and accurate VO2peak value, CS may be incorrectly evaluated, 
negatively altering their prescription of exercise and subsequent exercise intervention.  
The development of the RMCRI treadmill protocol is intended to be a cancer-specific 
protocol to determine VO2peak in CS.  Due to its low intensity progression, it allows 





pilot data conducted at our facility, to our knowledge, there have been no other cancer-
specific treadmill protocols evaluated for their validity. Specifically, there are no current 


















 Cancer is the second leading cause of death in the United States, and it may 
account for approximately 1,600 deaths per day.  Although prostate and breast cancer are 
the most prevalent for males and females, respectively, there are hundreds of different 
types of cancer, with lung and bronchus accounting for the greatest amounts of cancer 
deaths (ACS, 2015).  However, due to advancements in cancer treatment, the 5-year 
survival rate for all-site cancers diagnosed between 2003 and 2009 has been reported to 
be at 68%, which is up from the survival rate of 49% between the years of 1975-1977 
(ACS, 2015).  Early detection and advanced treatments are resulting in longer life spans 
for CS.  Nevertheless, cancer treatment-related side effects oftentimes negatively and 
severely affect a cancer survivor’s overall health and well-being, which highlights the 
importance of improving an individual’s quality of life (QOL), fatigue, depression, and 
physiological variables such as muscular strength, muscular endurance, and VO2peak.  
 Cancer itself can have many side effects on an individual, such as cancer cachexia 
or fatigue, but the side effects of cancer treatments can be just as devastating.  
Chemotherapy and radiation have been observed to reduce a client’s quality of life 
(QOL) (Dhillon et al., 2012), increase fatigue (Buffart et al., 2013), increase depression 





cardiovascular dysfunction (Schneider et al., 2007b; Smoot et al., 2012).  For clinicians 
and researchers, it is their objective to try and alleviate these side effects with the ultimate 
goal of increasing a survivor’s QOL.  For this reason, establishing a cancer rehabilitation 
program in order to address these issues is warranted. 
Fatigue in Cancer Survivors 
 
 Cancer-related fatigue (CRF) is one of the most common and prevalent side 
effects experienced by survivors.  It can be defined as a clinical entity that is described by 
tiredness to exhaustion that is not precipitated by activity, or if it occurs after activity, it is 
out of proportion to the level of exertion (Berger et al., 2012).  Bed rest has not been 
indicated to alleviate this type of fatigue, and it may actually worsen with physical 
inactivity.  It has been reported that 58-94% of breast CS experience some aspect of 
fatigue during treatment, while 56-95% may have fatigue once they have completed 
treatment (Berger et al., 2012).  In similar reports, it has been claimed that fatigue is 
experienced in 70-100% of CS (Cramp, 2012).  Cancer-related fatigue can persist for 
months or even years after treatments have been completed, and can affect an individual 
physically, mentally, and emotionally.  It has been cited that fatigue in cancer patients has 
been significantly higher than fatigue in the general public (p < 0.05), and that severe 
fatigue in cancer patients was greater than fatigue experienced by 95% of a AH control 
group (Stone & Minton, 2008).  In a similar study, it was observed that fatigue in 
survivors who did not have any type of rehabilitation after treatment worsened (Hayes et 






 Although fatigue can affect psychological well-being, it may also severely impair 
physical functioning such as self-care actions, mobility, and any recreational activity.  Of 
great concern, it has been reported that 91% of those who underwent chemotherapy stated 
that fatigue had changed their ability to perform daily activities, such as preparing food, 
cleaning, light lifting, and basic social activities (Hofman, Ryan, Figueroa-Moseley, 
Jean-Pierre, & Morrow et al., 2007).  Others have looked at how fatigue directly altered 
physical functioning by using an objective measure, such as the time it takes for an 
individual to rise from his or her chair.  It has been reported that survivors who had more 
fatigue had overall poorer physical functioning and took longer to rise out of a chair 
(Brown, McMillan, & Milroy, 2005).  In a similar setting, researchers have witnessed an 
inverse relationship between self-reported fatigue and overall physical functioning 
(Mallinson, Cella, & Cashy, 2006).  It is generally accepted that these impairments in 
physical functioning could be attributed to CRF.   
Cardiovascular Dysfunction 
 
 Cardiovascular function is one of the best ways of determining an individual’s 
overall fitness.  However, a disease such as cancer can drastically alter a survivor’s 
cardiovascular capabilities and health.  This may be due to the cancer itself, cancer 
treatments, deconditioning, age of patient at diagnosis, or any combination of these.  
Treatments with certain types of chemotherapy may result in cardiomyopathy, congestive 
heart failure, cardiotoxicities, and cardiovascular dysfunction (Doyle, Neugut, Jacobson, 
Grann, & Hershman, 2005; Gibson, Greufe, Hydock, & Hayward, 2013; Hayward, 
Hydock, Gibson, Bredahl, & Parry, 2013; Hydock, Wonders, Schneider, & Hayward, 





 Due to the many cardiovascular complications seen with cancer and cancer 
treatment, cardiovascular fitness in this population is often lower than age-matched AH 
populations.  It has been demonstrated that VO2peak can significantly differ between CS 
and the healthy population, specifically with CS consistently showing 30% lower VO2peak 
values than apparently healthy age-matched control groups (Smoot et al., 2012).  Not 
only were the survivors’ values lower than the AH, but their overall classification fell in 
the 30th percentile in the published healthy female age-matched norms, which is also 
categorized as “poor” (ACSM, 2013; Heyward & Gibson, 2014).  These findings suggest 
that CS will have an overall lower cardiovascular fitness level and may struggle on 
cardiorespiratory fitness protocols.  It also supports the notion that survivors need 
rehabilitation after any type of cancer treatment to regain their cardiovascular fitness.   
 Cancer treatments have advanced significantly in the past years with adjuvant and 
targeted therapies.  However, many studies have shown that treatments such as 
chemotherapy may lead to cardiomyopathy and cardiovascular toxicities, which in turn 
negatively affect cardiovascular function (Cardinale et al., 2010; Doyle et al., 2005; 
Hayward et al., 2013; Schneider et al., 2002; Schneider et al., 2007b; Vejpongsa & Yeh, 
2014).  Chemotherapy has been known to cause cardiotoxicity by reducing left 
ventricular ejection fraction, increasing time to peak filling of the left ventricle, and 
reducing stroke volume and cardiac output, which ultimately compromises oxygen and 
nutrient delivery to the body (Monsuez, Charniot, Vignat, & Artigou, 2010; Schneider et 
al., 2007b).  It has been noted that >50% of patients who experienced congestive heart 
failure had a 30% reduction in left ventricular ejection fraction, which has been reported 





most common chemotherapies include but are not limited to: alkylating agents, 
antimetabolites, topoisomerase inhibitors, mitotic inhibitors, and anthracyclines (ACS, 
2015).  These drugs will either damage, inhibit, or alter DNA to prevent cancer cells from 
reproducing.     
Anthracyclines, such as Doxorubicin (DOX), are one of the most effective types 
of chemotherapy used to treat malignant cancers; however, they are also the most 
cardiotoxic.  Cardiotxocity has been reported to occur following repeated bouts of dose-
dependent anthracycline administration, which has been speculated to be a function of 
cardiomyocyte apoptosis, oxidative stress, and/or disruption of myofibrils and contractile 
proteins (Richard et al., 2011; Eschenhagen et al., 2011).  Repeated exposure to 
anthracyclines may lead to cardiotoxicity months or even years after treatment, but acute 
cardiotoxicity can occur minutes after administration (Arola et al., 2000; Jantunen, 
Vanninen, & Hartikainen, 2002; Monsuez et al., 2010; Vejpongsa & Yeh, 2014; Shakir & 
Rasul, 2009;).  These cardiotoxicities may develop into cardiomyopathy or congestive 
heart failure (CHF) once treatment is completed (Monsuez et al., 2010; Hydock et al. 
2009, Shapiro & Recht, 2001).  It has been suggested that patients treated with DOX 
were 2.5 times more likely to develop cardiomyopathy than untreated clients (Doyle et 
al., 2005).  Additionally, CS who received treatment had a 4.1% incidence rate of 
developing cardiomyopathy, while those who did not receive chemotherapy had only a 
1.6% incidence rate.  However, after a five-year follow-up the incidence rate increased to 
5.0% and 10.2% for those who did not receive treatment and for those who did, 
respectively (Doyle et al., 2005).  It has also been reported that 7% of patients develop 





a continuum of increasing risk for CHF with accumulation of dosage (Swain et al., 2003).  
Those who have a cumulative dosage of 400 mg/m2, 550 mg/m2, and 700 mg/m2 of 
anthracyclines had a 3-5%, 7-26%, and 18-48% risk of developing CHF, respectively 
(Swain et al., 2003; Von Hoff et al., 1979).    
Cardiac dysfunction has been researched extensively in animal studies as well.  In 
the rat model, cardiac dysfunction has been compared between sedentary rats with no 
DOX treatment and sedentary rats injected with DOX.  Rats that were administered DOX 
experienced a significant decline in left ventricular developed pressure (-59%), maximal 
rate of left ventricular pressure development (-43%), and a 45% increase in lipid 
peroxidation (p < 0.05) (Wonders, Hydock, Schneider, & Hayward, 2008). When 
compared to control rats, DOX-treated rats experienced significantly lower left 
ventricular force production (p < 0.01), increased myocardial oxidative stress markers, 
and altered transcript levels for all measured markers of cardiac remodeling, except for 
vascular endothelial growth factor-A (p < 0.001) (Richard et al., 2011).  It’s also been 
observed that DOX administration in small doses over days or weeks has resulted in 
better survival rates than rats who were given a larger single dose of DOX (Hayward & 
Hydock, 2007).  
Pulmonary Dysfunction with  
Cancer Treatments 
 
 The assessment of pulmonary function allows clinicians to evaluate the damage 
done to the lungs and pulmonary system due to cancer or treatments.  Pulmonary toxicity 
may be acute or chronic, and may persist many years after treatment (Schneider et al., 
2002).  Radiation or a combined modality with chemotherapy has led to obstructive and 





expiratory capacity (FEV1), and impaired diffusion capacity (Beinert et al., 1996; 
Eisbruch et al., 2002; Horning, Adhikari, Hoppe, & Olshen, 1994; Jensen, Carlsen, 
Groth, & Nissen, 1990; Lehne, Johansen, & Fossa, 1993; Lund et al., 1995).  Treatments 
may cause pulmonary fibrosis and unusual development of pulmonary tissue, as well as 
radiation pneumonitis in patients who have undergone treatment for lung cancer.  This 
occurs in 5-15% of patients receiving external beam radiation, and the overall risk of 
radiation pneumonitis was 7.8% in those who underwent combined modality therapy for 
lung cancer (Carver et al., 2007).  Chemotherapy combined with radiation increases the 
chance of radiation pneumonitis to 11% (p = 0.001) (Carver et al., 2007), and the two 
year risk of interstitial pneumonitis has been seen to be 26.8% (Granena et al., 1993).  
Chemotherapy alone has also been observed to damage the diaphragm directly (Whitney 
& Sporn, 2014). 
 In animal models, cancer and cancer treatments have resulted in respiratory 
muscle dysfunction.  In cancer cachectic mice, mitochondrial respiratory chain 
complexes and oxygen consumption have been found to decrease in both the diaphragm 
and the gastrocnemius (Fermoselle et al., 2013).  Similarly, all diaphragm muscle fiber 
types have been observed to atrophy, experience weakness, and compromise ventilation 
due to cancer cachexia in mice models (Roberts et al., 2013).  Treatments such as DOX 
can negatively affect respiratory muscles, as it has been found that DOX significantly 
decreased diaphragm force as well as stimulate tissue inflammation and muscle fiber 
injury in the mouse model (Gilliam, Moylan, Callahan, Sumandea, & Reid, 2011).  
Damage to the pulmonary system may directly affect cardiovascular function 





transport and utilize oxygen, but these results may be affected if the pulmonary system is 
compromised.  Because oxygenated blood is pumped back to the heart via the lungs, lack 
of sufficient oxygen due to pulmonary dysfunction will affect cardiovascular fitness.  
Common respiratory symptoms include wheezing, dyspnea, shortness of breath due to 
wheezing, overall shortness of breath, and shortness of breath when in a hurry (Myers et 
al., 2005; Raber-Durlacher et al., 2012; Sarna et al., 2004).  Additionally, these 
investigators found that out of 142 CS, 38% walked slower than people their age because 
of breathlessness, 32% had to stop for breath when walking, and 11% were unable to 
leave their house because they were so breathless.  All of the aforementioned items will 
severely affect an individual’s cardiovascular system and fitness level.   
Importance of Physical Activity 
 
 A combination of early detection and advancements in cancer treatments are 
leading to better prognoses in CS.  However, side effects such as fatigue and decrements 
to the cardiovascular system may cause patients to become physically inactive which may 
in turn lead to cardiovascular complications (Jones et al., 2009; Lakoski et al., 2012).  
Cancer patients report a decrease in time spent for exercise once radiation treatments start 
and they were less likely to engage in strenuous activities (Murnane et al., 2012).  In one 
study, physical activity decreased by 50% after undergoing surgery, radiation, and/or 
chemotherapy (Kim et al., 2006).  The reduced physical activity and cardiorespiratory 
fitness could also be associated with functional dependence, a loss of energy, and 
possibly an increase in cardiovascular morbidity and mortality (Lakoski et al., 2012).  
About 70% of cancer patients do not meet the US national exercise recommendations, 





Courneya, & Stein, 2008; Denmark-Wahefried, Peterson, McBride, Lipkus, & Clipp, 
2000).   
Other studies report physical inactivity in up to 75% of CS (Coups & Ostroff, 
2004; Denmark-Wahnefried, Peterson, McBride, Lipkus, & Clipp, 2000) and 28-41% in 
breast CS (Pinto & Maruyama, 1999).  Similarly, other researchers have stated that only 
30-47% of survivors are meeting the daily physical activity requirement, and that the 
percentage of CS who were met ACSM’s recommendations for physical activity (29.6%) 
was lower than those who did not have cancer (37%) (Blanchard, Courneya, & Stein, 
2008).  Interestingly, others have stated that long time breast CS were 42% more likely to 
perform vigorous physical activities than healthy controls, as well as 28% more likely 
than controls to meet physical activity recommendations (Bellizzi, Rowland, Jeffrey, & 
McNeel, 2005; Blanchard et al., 2010).  This finding is encouraging because it suggests 
more survivors are incorporating physical activity into their daily lives.   
Physical inactivity is a strong influencing factor of low cardiorespiratory fitness 
as well as cancer mortality, and may decondition skeletal muscles and impair 
cardiopulmonary function (Kim et al., 2006).  Three weeks of inactivity can lead to a 
significant decrease in cardiac output, oxidative capacity, VO2peak, and muscle cross 
sectional area (Saltin et al., 1968).  There is also evidence to suggest that decrements in 
physical activity may be associated with cardiac events and potentially death in both men 
and women (Gulati et al., 2003).  In fact, some researchers state that peak exercise 
capacity is one of the strongest predictors of the risk of death, and has been seen to be 
even more powerful than other established risk factors for cardiovascular disease 





as it has been observed that cardiorespiratory fitness decreases around 10% per decade of 
life (Eskurza, Donata, Moreau, Seals, & Tanaka, 2002; Fitzgerald, Tanaka, Tran, & 
Seals, 1997; Jones et al., 2009; Lakoski et al., 2012).  In a particular study, thirty years of 
aging reduced VO2peak about 20%, with physical inactivity accounting for as much as 
40% of the decline (Jones et al., 2009).  VO2peak itself can be a predictor of mortality, as it 
has been reported that a 1 mL·kg-1·min-1advantage in VO2peak was associated with a 10% 
lower cardiac mortality risk (Kavanagh et al., 2003).  Also, three weeks of inactivity can 
result in approximately a 35% decline in VO2peak (Peel et al., 2009). What is most 
disconcerting is that peak oxygen uptake seems to be lower after thirty days of bed rest 
than after thirty years of aging (McGuire et al., 2001).  On the Framingham risk score 
(FRS), which is an equation that estimates the ten year cardiovascular risk of an 
individual, it is stated that every one metabolic equivalent (MET) decrease in the FRS 
was associated with a 9% increased risk of death (p < 0.001) (Gulati et al., 2003).   
The importance of increased physical activity has been well documented.  An 
ACSM roundtable of experts in cancer and exercise deemed that physical inactivity 
should be avoided at all costs (Schmitz et al., 2010).  Cancer survivors who regularly 
exercise or who are physically active during or after treatments have significantly better 
physical functioning, cardiorespiratory fitness, psychological well-being, and QOL 
compared to those who did not (Brown et al., 2010; Dimeo et al., 1997; Murnane et al., 
2012).  In a study of 260 breast CS, a significant correlation between physical activity 
and cardiorespiratory fitness was observed (r = 0.35, p < 0.01), stating that more 
physically active clients had better their cardiovascular function (Taylor et al., 2010).  





function have a greater life expectancy as well (Blair et al., 1989; Blair et al., 1995; 
Kannel, Wilson, & Blair, 1985; Peel et al., 2009).  Every one MET increase in exercise 
capacity has been related to a 12% improvement in survival, as well as a 17% decrease in 
mortality risk on the Framingham risk score (Gulati et al., 2003; Myers et al., 2002).  It 
has been observed in CS that simply walking for one hour per week improved survival 
over those who were physically inactive, and that walking for 3 hours per week was 
associated with a decreased risk of mortality (Holmes, Chen, Feskanich, Kroenke, & 
Colditz, 2005).  Physical activity of greater than three hours has shown benefits as well, 
as the 5-year survival rate for those who engage in 3 to 8.9 hours and >9 hours of 
physical activity was 93% and 97%, respectively (Holmes et al., 2005).   
Although any amount of physical activity is beneficial, there are claims that 
physical activity only offers protective benefits when the intensity is at eight METs or 
greater (Peel et al., 2009).  The same researchers claimed that women with an exercise 
capacity less than eight METs had nearly a threefold higher risk of dying than those with 
higher MET values.  Additionally, in a study where CS were divided into an exercise or 
sedentary group for sixteen weeks, it was observed that physical activity levels did not 
differ between the two groups.  However, only the exercise group showed a within-group 
significant increase in voluntary activity and energy expenditure, as well as a decrease in 
sedentary activity (Kim et al., 2009).  Although some researchers believe there is a 
minimum intensity at which physical activity is beneficial, all agree that some physical 









Benefits of Exercise on Cancer Related-Fatigue  
and Cardiopulmonary Function 
 
Exercise has been demonstrated to improve psychological factors such as cancer-
related fatigue (Schmitz et al., 2010; Schneider et al., 2007b; Yeo et al., 2012). Following 
a six-month exercise program that included individualized cardiorespiratory, strength, 
and flexibility training, survivors who were both in and out of treatment saw reductions 
in overall fatigue (Schneider et al., 2007b).  Decreases in fatigue have ranged from -32 to 
-39% and -33 to -39%  during and following treatment, respectively (Schneider & 
Hayward, 2013).  However, it has been suggested that patients who are currently 
receiving treatment may see the largest improvements in fatigue, while those who had 
recently finished treatment should have longer durations between treatment and exercise 
initiation, and adhere to a shorter exercise program length (Puetz & Herring, 2012).  
Regardless, the investigators concluded that exercise may be a factor in the reduction of 
fatigue in clients both in treatment and following treatment. Various non-traditional types 
of exercise interventions have also been implemented with success.  When exercise was 
prescribed over the phone to survivors for six weeks, a decline in fatigue was observed 
(Hayes et al., 2013).  It was deemed that even if a survivor couldn’t see an exercise 
physiologist face-to-face, indirect verbal communication was effective in improving 
fatigue.   
In recent meta-analyses, it has been concluded that exercise interventions, 
whether it be face-to-face or over the phone, successfully reduced fatigue variables when 
compared to a sedentary control group (Brown et al., 2010; Carayol et al., 2013; Puetz & 
Herring, 2012).  It has been proposed that 90-120 minutes of weekly moderate physical 





exercise has provided some of the greatest reductions in fatigue, as have moderate 
intensity resistance training programs (Brown et al. 2010; Burnham & Wilcox, 2002; 
Carayol et al., 2013; Cramp & Byron-Daniel, 2012).  Interestingly, in a study where 
home-based exercises were performed by CS, fatigue was not significantly reduced 
compared with sedentary controls.  It was also stated that no intervention type 
(supervised resistance training, supervised aerobic training, or home-based training) 
offered a significant advantage over another in reducing fatigue (Velthuis, Agasi-
Idenburg, Aufdemkampe, & Wittink, 2010).  Similarly, a review of literature revealed 
that while aerobic exercise has been reported to significantly reduce fatigue levels 
amongst CS, resistance training and alternative forms failed to reach significant 
improvements (Cramp & Byron-Daniel, 2012).  Despite conflicting research, exercise has 
been shown to diminish fatigue to varying degrees. 
The cardiorespiratory system may improve in CS undergoing treatment as a result 
of exercise.  Aerobic exercise may reduce the risk of heart disease and protect the heart 
against injury caused from oxidative stress, which in turn can help offset some of the 
negative cardiovascular side effects caused by treatments.  In fact, in those receiving 
adjuvant therapy, exercise was capable of significantly reducing survivors’ resting heart 
rate and resting systolic blood pressure (SBP) (Dimeo et al., 1997; Schneider et al., 
2007b). Additionally, it has been observed that exercise improved cardiac output, stroke 
volume, and increased arteriovenous oxygen differences, which may have led to an 
increase in functional capacity in these CS (Kim et al., 2006; Schneider et al., 2007b).  
Whole-body exercise has been shown to be efficient in attenuating chemotherapy-





during treatment (Schmitz et al., 2010).  A common deleterious symptom of 
cardiotoxicity is a shift in cardiac myosin heavy chain (MHC) isoform from α to β.  
These isoforms encode cardiac muscle-specific proteins involved in force generation 
(Molkentin, Jobe, & Markham, 1996).  In a study where rats treated with DOX remained 
sedentary or were allowed 24-hour access to voluntary wheel running cages, expression 
of cardiac β-MHC was 43 + 7% of the total MHC isoform while it was only 24+4% β-
MHC isoform in exercised animals (Hydock et al., 2009).  This exercise-induced 
preservation of MHC isoform distribution was associated with a maintenance of cardiac 
function.  Similarly, it has been reported that even a single bout of acute endurance 
exercise twenty-four hours before the administration of DOX has a cardioprotective 
effect.  This single bout of exercise decreased end systolic pressure, left ventricular 
developed pressure, and the maximal rate of left ventricular pressure development 
(Wonders et al., 2008).  Correspondingly, rats who performed an acute bout of exercise 
before DOX administration were able to reduce the amount of myocardial oxidative 
damage and dysfunction (Ji & Mitchell, 1994).  Acute exhaustive exercise after DOX 
administration also increased the survival rate of rats (Combs, Hydman, & Bonner, 
1979).  This supports the concept that exercise before or after treatment may attenuate 
cardiotoxicity.   
Pulmonary function can be improved due to exercise, as shown by increases in 
percent of predicted forced vital capacity, forced expiratory volume, and overall lung 
function in both during and after treatment (Marulli et al., 2010; Schneider et al., 2007b).  
It has been observed that regular exercise strengthens the respiratory muscles and will 





cardiovascular systems (Zolaktaf, Ghasemi, & Sadeghi, 2013).  Additionally, respiratory 
and pulmonary rehabilitation that includes aerobic and muscular endurance training, has 
shown to improve QOL and exercise tolerance in those with chronic obstructive 
pulmonary diseases (Nici et al., 2006).  It’s also been observed that pulmonary 
rehabilitation that includes low-intensity endurance and strength training has resulted in a 
reduction of expiratory flow limitations as well as hyperinflation of the lungs at rest 
(Yoshimi et al., 2012).   
Benefits of Exercise on Exercise Capacity and Peak 
Volume of Oxygen Consumption  
 
 Cardiorespiratory fitness is a reflection on the overall fitness of the body, with 
VO2peak being a primary variable used to assess the cardiovascular system.  With CS, an 
exercise intervention is used to increase this variable along with many others, such as 
physical performance.  Baseline VO2peak measures are generally higher in those who are 
physically active than those who are sedentary (Bruce, Kusumi, & Hosmer, 1973; 
Watchie et al., 1986).  For those that perform weekly physical activity, VO2peak has been 
seen to significantly increase compared to those who do not (Kim et al., 2006; Marulli et 
al., 2010; May et al., 2010).  A recent meta-analysis stated that aerobic exercise 
successfully increased CS’ VO2peak when compared to sedentary control groups (Jones et 
al., 2011), where improvements in VO2peak have varied from 2 to 40% (Garner & Erck, 
2008; Jones et al., 2011; Kim et al., 2006; Klika, Callahan, & Drum, 2009; Marulli et al., 
2010; McNeely et al., 2006; Schneider et al., 2007b).  The improvements in VO2peak may 
vary depending on the type of exercise intervention or on individual survivor 
characteristics.   Physical exercise can also improve the performance on an aerobic test, 





Hsieh, Hayward, & Schneider, 2010).  Specifically for clients who were both in and out 
of treatment, treadmill time has been seen to increase from baseline to post assessments 
by as much as 28% (Schneider et al., 2007b).   
Cancer Rehabilitation Programs 
 
 With advancements in diagnosis and treatments for cancer, survival rates are at an 
all-time high.  However, treatments are leaving CS with side effects such as fatigue, 
depression, and reduced QOL.  In 1970, the National Cancer Act was passed to aid 
federal efforts in fighting cancer.  It created the National Cancer Program, which is 
directed by the National Cancer Institute.  In doing so, the act has funded thousands of 
researchers and programs in hospitals and other medical facilities in every state to 
improve cancer diagnosis, treatment, and care.  However, due to earlier detection, 
advanced treatments, and improvements in technology, hospital and postoperative based 
rehabilitation programs virtually disappeared over the years (Alfano, Ganz, Rowland, & 
Hahn, 2012).  Today, with over 1.6 million new diagnoses of cancer to be expected, the 
need for cancer rehabilitation is receiving attention once again (ACS, 2015).   
 The need for cancer rehabilitation has been researched by mailing surveys to CS.  
Surveys have addressed satisfaction of current rehabilitation services as well as services 
and factors that were unmet.  The most sought service that was currently unavailable was 
physical therapy, followed by physical training, psychological counseling, and 
occupational therapy.  It was reported that 63% surveyed conveyed a need for at least one 
of the aforementioned services, while 40% stated that none of their rehabilitation needs 





patients are interested in physical activity counseling (Jones & Courneya, 2002; 
Stevinson et al., 2009).   
 Different organizations such as the American College of Sports Medicine 
(ACSM), American Cancer Society (ACS), and the World Cancer Research 
Fund/American Institute for Cancer Research (WCRF/AICR) have established physical 
activity guidelines for CS.  Cancer rehabilitation programs are slowly starting to form in 
hospitals and businesses such as the Young Men Christian Association’s (YMCA) 
gymnasiums, but most do not have a model program to assist survivors.  Programs need 
to be carefully structured and rigidly controlled where all patients should be assessed and 
reassessed to evaluate progress.   
A clinical program should have designed interventions structured to address and 
treat the following toxicities: cardiovascular, pulmonary, gastrointestinal, 
musculoskeletal, immune, hematological, and neurotoxicity (Schneider et al., 2002).  
Established programs should aim to provide scientifically based individualized 
prescriptive exercises for patients, provide ongoing basic and clinical research for 
alleviating cancer related symptoms, and advance educational preparation and 
professional development to promote high standards for cancer rehabilitation.  The Rocky 
Mountain Cancer Rehabilitation Institute (RMCRI) is an established clinic that has all the 
necessary tools and protocols to address the aforementioned goals.  Additionally, 
research conducted at RMCRI has shown that exercise interventions in CS provide 
significant improvements in functional capacity, resting heart rate, time on treadmill, 
FVC, range of motion, muscular strength and endurance, VO2peak, and psychological 





Schneider, Dennehy, & Carter, 2003; Schneider et al., 2002; Schneider, Stephens, Quick, 
& Carter, 2000; Sprod et al., 2010).  With the increased need of structured cancer 
rehabilitation programs, there is a need for accurate assessments and exercise 
prescriptions to document changes in a cancer survivor’s overall health.  An accurate 
measure of maximal volume of oxygen consumed during exercise is an excellent 
indicator of overall health (Jones et al., 2011; Jones et al., 2005; McNelley et al., 2006). 
Clinical Maximum Volume of Oxygen  
Consumption Assessment 
 
The term maximum volume of oxygen consumed (VO2max) can be defined as an 
individual’s maximum oxygen consumption (VO2) during maximal work.  The ability to 
deliver oxygen to metabolically active skeletal muscles and other systems of the body for 
ATP re-synthesis is an essential need for humans.  VO2 increases proportionally to 
exercise intensity.  When oxygen consumption increases, it is dependent on the total 
amount of blood pumped by the heart and is redistributed to the working muscles (Smith 
& Fernhall, 2011). Greater measures of VO2 have been associated with reduced all-cause 
and cancer mortality (Gulati et al., 2003; Myers et al., 2002; Sawada et al., 2003; 
Kavanagh et al., 2003).  VO2max can be expressed in absolute terms (L/min) or in relative 
terms (mL·kg-1·min-1).  Absolute VO2 provides a measure of energy cost on non-weight 
bearing activities such as cycling or arm ergometry (Heyward & Gibson, 2014).  In most 
instances, VO2 is conveyed relative to an individual’s body weight in kilograms (kg), 
which allows clinicians to compare individuals of different body masses, as well as 
calculate energy cost of weight bearing activities (walking, running).  Relative VO2 is 





kilogram of body weight every minute.  The resting relative VO2 is about 3.5 mL·kg
-
1·min-1, which is equivalent to one MET.   
The measurement of VO2max has been deemed the most valid representation of 
oxygen consumption (Brooks et al., 2005; Hawkins et al., 2006; Heyward & Gibson, 
2014; Jones et al., 2008; Kim et al., 2006).  Typically a VO2max test uses GA via a 
metabolic cart to measure the participant’s oxygen consumption.  However, to do a valid 
and reliable VO2max test, one needs the proper equipment and personnel for accurate 
results.  Also, a true VO2max test requires the patient to exercise until complete exhaustion 
(plateau in VO2, RER >1.15, blood lactate >8 mmol), which may be dangerous or even 
impossible for some.  Factors such as the expense of the equipment, the lack of trained 
personnel, physical limitations, lack of motivation, persistent fatigue, and impact on a 
patient may not make a VO2max test feasible or valid for special populations (Jones et al., 
2008; Pina & Karalis, 1990; Stone et al., 2011). 
Due to the strict criteria that must be met in order to establish a reliable and valid 
VO2max, a VO2peak test is often used instead.  VO2peak is an objectively measured variable 
and can be defined as the highest VO2 achieved during an exercise test, typically via a 
metabolic cart (Heyward & Gibson, 2014; Jones et al., 2011; Pina & Karalis, 1990;).  
VO2peak tests are often shorter due to termination criteria, require less equipment, less 
effort, and yield similar results to VO2max tests.  In fact, it has been observed that there are 
no significant differences in final VO2 values between a VO2peak and a VO2max test (Day, 
Rossiter, Coats, Skasick, & Whipp, 2003; Eldridge, Ramsey-Green, & Hossack, 1986; 
Hawkins et al., 2006; Howley, 2007; Jones et al., 2011).  During a peak test, the subject 





determining whether they reached physiological exhaustion.  However, many of the peak 
VO2 tests are geared towards the healthy populations, not the cancer population.  Less 
intense protocols would be beneficial and more accurate for those who have undergone or 
are currently undergoing cancer treatment and are suffering from the deleterious side 
effects. 
Validity of Maximum Volume of Oxygen  
Consumption Assessments 
 
GA have been considered to be the gold standard for measuring VO2 because of 
the direct measurement of oxygen consumption (Waddoups, Wagner, Fallon, & Heath, 
2008).  This type of analysis uses a respiration mask that is connected to a metabolic cart.  
The metabolic cart is capable of directly measure the amount of oxygen (O2) consumed, 
the amount of carbon dioxide (CO2) expelled, and the respiratory exchange ratio (RER).  
The RER is the ratio of the amount of CO2 expelled compared to the amount of O2 
consumed.  It may also measure ventilation and other pulmonary values as well.  
However, due to the expenses of obtaining a metabolic cart, predictive VO2 equations 
have been used to estimate VO2max.  These equations have been deemed accurate as long 
as the VO2 protocol is valid and reliable, and may vary depending on whether the test is a 
submaximal, maximal, or peak test (ACSM, 2013).  Submaximal VO2 tests generally end 
at a pre-determined stopping point (% heart rate max/heart rate reserve).  Submaximal 
tests have been found to be a feasible alternative to maximal tests and ultimately look to 
estimate an individual’s VO2max (May et al., 2010; Heyward & Gibson, 2014).  Specific 
walking and running equations developed by ACSM are used in many VO2max prediction 
equations and accurately predict energy expenditure when steady state VO2 is achieved 





submaximal VO2 and ACSM prediction equations has been seen to be 0.92 (Bader, 
Maguire, & Balady, 1999). 
  Some of the most common treadmill protocols include but are not limited to: the 
BTP, the modified BTP, and the Balke.  The BTP has been validated as an accurate 
measurement of VO2max and is one of the most used treadmill protocols (Akinpelu et al., 
2014)  ACSM’s walking and running equations are used in the multi-stage model VO2 
prediction equations for a submaximal BTP (Heyward & Gibson, 2014; ACSM, 2013).  It 
has been reported that the correlations between Bruce’s predicted VO2max and the 
observed VO2max was 0.94 in patients without cardiac conditions and 0.87 for men with 
cardiac disease (Bruce, Kusumi, & Hosmer, 1973).  However, this test includes drastic 
increases in both speed and incline, which might not be suitable for the cancer 
population.  Research suggests that protocols with larger increments between stages 
result in an overestimation of VO2peak and show greater variability (Bader, Maguire, & 
Balady, 1999).  Similarly, Bruce estimations of VO2max have been overestimated by 4 
mL·kg-1·min-1 in sedentary groups (Pollock et al., 1982), while others have been seen to 
significantly underestimate the prediction of VO2max.  It’s been stated that the prediction 
equations would be most valid in average to above average fitness populations who are 
between 20 and 40 years of age (Pollock et al., 1982). 
 Due to the difficulty of current protocols, less intense protocols such as the 
modified BTP and Balke may be more appropriate for high risk clients.  The exercise 
intensity of the modified BTP does not increase as drastically as the BTP, and can 
calculate estimated VO2max by using ACSM’s walking/running equations (Heyward & 





equations as well, and has been found to have a correlation of 0.92 between predicted and 
actual VO2max (Pollock et al., 1976; Pollock et al., 1982).  Other protocols such as, but not 
limited to, the United States Air Force, modified Balke, Naughton, modified Naughton, 
and Balke-Ware protocols have also shown high correlations with observed VO2max 
(ACSM, 2013; Balke & Ware, 1959; Naughton & Nagle, 1965; Patterson, Naughton, 
Pietras, & Gunnar, 1972; Wolthuis et al., 1997). 
There have been both similarities and discrepancies when correlating VO2max 
values between different protocols.  The modified BTP and Naughton protocols have 
been found to produce a similar VO2peak in cardiac patients as well as detecting ischemic 
abnormalities (Handler & Sowton, 1984; Naughton & Nagle, 1965; Strzelczyk, Cusick, 
Pfeifer, Bondmass, & Quigg, 2001;).  However, other studies have observed that the 
Naughton protocol was not suitable for some elderly individuals due to the exhaustion 
caused by the protocol, while the BTP was more efficient and obtained the largest 
number of diagnostic tests with a significantly lower number of inconclusive tests 
(Aguiar et al., 1997; Strzelczyk et al., 2001).  When comparing the Balke to the BTP, the 
Balke produces slightly lower VO2max values that are statistically non-significant 
(McArdle, Katch, & Pechar, 1973; Moody, Kollias, & Buskirk, 1969; Pollock et al., 
1982).  When compared to the modified BTP, the Bruce treadmill protocol elicits higher 
physiological stress variables such as heart rate, blood pressure, and capacity of peak 
exercise (Trabulo, Mendes, Mesquita, & Seabra-Gomes, 1994).  Interestingly, some have 
suggested that a modified BTP is unnecessary because any patient can undergo testing 





As already stated, there have been high correlations found between VO2max and 
VO2peak tests (Day et al., 2003; Eldridge et al., 1986; Hawkins et al., 2006; Howley, 2007; 
Jones et al., 2011).  Similarly, it has been suggested that submaximal testing does provide 
a reasonable alternative to VO2max testing in CS (May et al., 2010).  The relationship 
between VO2 attained via a submaximal test and predicted VO2max during a ramp protocol 
was 0.92 (Bader et al., 1999), and a correlation of 0.96 was observed between observed 
VO2max and estimated VO2max in healthy individuals (Ebbeling, Ward, Puleo, Widrick, & 
Rippe, 1991).  Although submaximal tests are feasible, it is still recommended that CS 
undergo an exhaustive exercise assessment before the start of an exercise program (May 
et al., 2010).  Some have stated that the predictive validity of a submaximal test 
diminishes at the extremes of specified heart rate ranges (Waddoups et al., 2008).  A 
submaximal BTP results in lower predictive VO2max values and shows no significant 
correlation with a maximal BTP (Dabney & Butler, 2006).  Another study found that 
there was only a moderate correlation between a VO2max test and a submaximal test, 
whereas there was a high correlation between a VO2max test and a steep ramp test (De 
Backer et al., 2007).  The same authors concluded that the submaximal test produced 
invalid results, where the steep ramp protocol seems to be practical, reliable, and valid.  
Submaximal outcomes for loading capacity may be inaccurate and may not represent an 
individual’s true VO2max.  It has also been reported that submaximal tests overestimated 
VO2max in healthy subjects, and that submaximal tests seem to be of less value for training 
guidance in CS, and may have limited value in assessing the exercise capacity (De 





Although the treadmill is one of the most common methods for testing for VO2, 
other modes such as cycle ergometers may also be used.  Cycle ergometer protocols are 
used to predict VO2 max in many clinical settings (De Lucas, Rocha, Burini, Greco, & 
Denadai, 2003; Fitchett, 1985; Vanderburg, 1993; Sport, Williford, Wang, Olson, & 
Blessing, 1993).  However, there have been significant differences found in maximal data 
between cycle ergometer and treadmill protocols (Astrand & Rodahl, 1977; Moody et al., 
1969; Pollock et al., 1982; Pollock, Dimmick, Miller, Kendrick & Linnerud, 1975).  
When compared to cycle ergometer protocols, VO2max values have been 5 to 11% higher 
on the treadmill (Astrand & Rodahl, 1977; McArdle et al., 1973; Moody et al., 1969;  
Pollock et al., 1982).  There has been only one study that shows similar findings in 
maximal heart rate (HR) between the two protocols (McArdle et al., 1973).  Peak VO2 
observed during the BTP has also been significantly higher than that on the cycle 
ergometer (Strzelczyk et al., 2001).  Mean peak VO2 has been observed to be higher on 
both the BTP and the modified Naughton than on the bike.  Interestingly, the BTP has 
been preferred over both the Naughton and cycle ergometer protocols (Strzelczyk et al., 
2001).  In a study where a submaximal YMCA cycle ergometer test and BTP were 
compared, predicted VO2max was less on a cycle ergometer than it was for a maximal BTP 
(Dabney & Butler, 2006).  In opposition to this finding, cycle ergometry has been 
moderately correlated with maximal exercise testing (De Backer et al., 2007).  When CS 
performed a submaximal cycle ergometer test, VO2max test, and a steep ramp test during 
an initial assessment and a reassessment, overall VO2max values improved.  Remarkably 
though, a significant improvement in VO2max was only seen pre-to-post in the ramp test, 





cycle and treadmill have been observed, when clients have adequate cycle training the 
results seem to equalize between the protocols (Pollock, Dimmick, Miller, Kendrick, & 
Linnerud, 1975).    
Cancer Specific Cardiovascular Testing 
 
Cancer survivors can utilize established protocols such as the BTP to determine 
their VO2peak, but the values may be inaccurate due to aforementioned factors.  The BTP 
and Balke protocols were meant to be tested on AH populations.  Additionally, the multi-
stage model equations for the BTP are only valid when the test is a submaximal test due 
to steady state VO2 (Heyward & Gibson, 2014).  There are population specific and 
generalized equations to estimate VO2peak for the BTP, but they are only appropriate for 
active and sedentary genders, as well as cardiac and elderly persons (Foster et al., 1984; 
Foster et al., 1983; Heyward & Gibson, 2014; Pollock et al., 1982).  None of the 
aforementioned categories exclusively include all CS.  Since survivors do not fit in any of 
these classes, estimated VO2peak through these equations may prove to be invalid or 
inaccurate.   
To date there is no cancer-specific cardiovascular treadmill test.  Cancer survivors 
experience many cancer and treatment-related side-effects and toxicities, such as 
ambulatory difficulties, peripheral neuropathy, balance difficulties, and neuromuscular 
dysfunctions, which may affect an individual’s ability to achieve an accurate and valid 
VO2peak (Wampler et al., 2007; Winters-Stone et al., 2011).  Cancer survivors have a 
higher risk of injury due to falling than AH populations, (Stone et al., 2011; Winters-
Stone et al., 2011) and established protocols such as the BTP increase in intensity too 





this, established protocols may not be able to establish a safe, reliable, and valid VO2peak.  
RMCRI established a treadmill protocol that was specifically developed for CS.  Unlike 
most treadmill tests, the RMCRI protocol increases intensity at a low but effective rate.  
There are no drastic increases in incline like the BTP and no constant speeds that may be 
too fast for CS, observed in the Balke protocol.  Instead, survivors are able to start off at a 
very low intensity and gradually work their way to a higher intensity.  The smaller grades 
and lessened speeds accommodate any probable conditions caused by cancer treatments 
such as pulmonary, musculoskeletal, and cardiovascular dysfunctions.  The goal of the 
RMCRI protocol is to have survivors reach VO2 values close to maximal without having 
to stop early due to factors other than cardiovascular function.  No studies have been 












A total of 60 subjects participated, which was determined by a power analysis 
before the start of the study.  Participants who are CS (n=45) were enrolled in the Rocky 
Mountain Cancer Rehabilitation Institute’s cancer rehabilitation program.  Inclusion 
criteria for cancer survivor subjects were 1) diagnosed with cancer, 2) at least 18 years of 
age, and 3) no history of stroke, chronic respiratory difficulties, or severe arterial 
hypertension (resting systolic blood pressure >200 mmHg, resting diastolic blood 
pressure 110, or both).  The CS medical history were known by faxed medical records 
from the participant’s oncologist or physician.  Recruitment occurred by placing fliers 
detailing information about the study around the institute, as well as the head researcher 
talking to CS directly.  Participants were explained that they will be partaking in a 
treadmill validation study, where they will perform three separate treadmill tests over the 
course of three weeks.  Those who participate were offered three months of free training 
at RMCRI.  If a cancer survivor had a question about the study, they were informed to 
ask the lead researcher.  
Apparently healthy control subjects (n= 15) were referred from the local 





that described the study was sent out to the entire College of Natural and Health and 
Sciences Department at UNC, asking for volunteers to participate.  Fliers were also put 
up at local gyms and recreational centers.  If a control subject was interested or had 
questions, they contacted the lead researcher.  Apparently healthy control participants 
were required to fill out a Physical Activity Readiness Questionnaire (PAR-Q) to 
determine whether they were eligible to participate in physical exercise (see Appendix 
A).  If a participant answered “yes” to any of the PAR-Q’s questions, that individual was 
not allowed to participate in the study.  If a control subject was deemed capable to 
participate in physical activity, the subject was required to fill out a medical history form 
(see Appendix B).  This medical form history evaluated pre-existing medical conditions 
that determined whether or not the participant met inclusion criteria.  Inclusion criteria 
for the control subjects were 1) no history of cancer, 2) at least 18 years of age, 3) no 
history of stroke, chronic respiratory difficulties, or severe arterial hypertension (resting 
systolic blood pressure >200 mmHg, resting diastolic blood pressure 110, or both), and 4) 
have an answer of “no” to all PAR-Q questions.  
Exclusion criteria for all subjects included 1) history of congestive heart failure, 
2) history of myocardial infarction, 3) chronic lung disease, 4) asthma, 5) significant 
ambulatory issues, 6) history of coughing up blood, 7) fainting, 8) epilepsy, and 9) 
neuropathy in the lower extremities.  Each protocol and test were explained in detail to 
each subject.  Safety was ensured by having a minimum of three Cancer Exercise 
Specialists (CES) present during each test, each having his or her own responsibility.  
When each subject fully understood the study, each test and protocol, and the 





has been approved by the University of Northern Colorado’s Institutional Review Board 
(see Appendix D).  
Experimental Design 
 
The purpose of this study was to assess the construct validity of the RMCRI 
multi-stage treadmill protocol for a cancer-specific population against standard metabolic 
GA and the BTP.  Participants who qualified for the study were randomly assigned an 
order of the three different protocols through a Statistical Analysis System (SAS) 
randomization code (SAS, 9.3).  Three separate treadmill tests were performed over three 
weeks.  A week of rest following each treadmill test was given to allow subjects to 
recover and reduce the risk of fatigue.  Cancer survivor participants may have been 
currently receiving cancer treatments during the study.  Therefore, if a CS was scheduled 
to perform a treadmill test within three days after a treatment, then that individual was 
allowed to perform their assigned VO2peak test the following week.  The following 
protocols were performed: a RMCRI VO2peak test using gas analysis (RGAP), a VO2peak 
Bruce treadmill protocol (BTP), and a RMCRI VO2peak test without gas analysis 
(RWOGAP).  Construct validity will be used to evaluate the RMCRI protocol.  Construct 
validity refers to whether variables of a test or instrument accurately measures the 
variable that they are intended to measure.  It was measured by comparing the variable 
achieved from the test or instrument being examined to the variable achieved from an 
established, reliable, and valid method.  This was accomplished by accumulating 
evidence from correlation coefficients, ANOVA demonstrating differences between 
groups, pre-test and post-test interventions, and factor analyses.  To calibrate the 





piece of tape was then be placed on the belt, and one piece of tape on the deck adjacent to 
the belt, and the treadmill was then set a particular speed.  A researcher observed how 
long (seconds) it took to see 20 revolutions of that piece of tape.  To determine the speed, 
the belt length was multiplied by the number of revolutions, and then divided by the time 
measured to complete the set of revolutions.  This was then repeated for increments of 
1mph from the range of 1 mph to 7 mph. 
To ensure a CS was fit to complete a VO2peak  test, each CS was required to 
complete the Feeling Scale of Exercise Scale (see Appendix E) before every VO2peak test.  
If a cancer survivor scored < -2 then that individual was not allowed to attempt a VO2peak  
peak test, and attempted the test the following week.  Resting blood pressure (BP), heart 
rate (HR), and blood oxygen saturation (SpO2) was measured before each test, along with 
the subject’s body weight (kg).  Blood pressure was determined using manual 
auscultation, heart rate was determined using a Polar® heart rate monitor, and SpO2 was 
determined using a Clinical Guard ® pulse oximeter.  During each test, SpO2, HR, and 
rating of perceived exertion (RPE) was recorded.  Certified Cancer Exercise Specialists 
(CES) conducted all treadmill tests to ensure safety.  One CES was responsible for 
changing the grade and speed of the treadmill during the protocol and record all 
information during the test, a second measured BP, a third stood behind the treadmill to 
spot the subject, and a fourth set up and operated a metabolic cart when necessary.  
Unless a subject felt uncomfortable, CES’s suggested that the participant not hold onto 
the handrails during the tests.  If a subject choose to hold onto the handrails, they were 
required to hold onto them for the entirety of the test.  Each participant was encouraged 





deemed a VO2peak test if at least two of the following criteria were met: 1) subject 
terminated test due to self-reported maximal effort and fatigue, 2) highest heart rate 
achieved was within ten beats per minute of the individual’s estimated heart rate max 
using the equation: 208 – (0.7*age), and 3) if a subject gave a RPE value on the modified 
Borg RPE scale of at least an eight.  If at least two of these criterion were not met, the test 
results were not used. 
Before each test began, the participants were given the following instructions: 1) 
one CES will be taking your blood pressure once every three minutes, 2) another CES 
will be recording all data from the test, as well as changing the speed and grades of the 
treadmill, 3) a pulse oximeter will be placed on your index finger, in which we will 
record your oxygen saturation at the end of every minute, 4) another CES will be 
standing behind the treadmill for spotting purposes, 5) we would like you to push 
yourself to what you feel is your maximum exertion; you may stop the test at any point, 
but we would like you to reach the point where you feel you cannot physically continue, 
6) we recommend you do not use the handrails, but you may if you feel it’s necessary, 7) 
regardless whether you choose to use or not to use handrails, you must choose one for the 
entire duration of the test, you may not go back and forth, and 7) once you reach 
perceived maximal exertion, we will begin a cool-down to lower your vitals close to 
resting measures.   
Four different VO2peak values were compared using a repeated measures ANOVA: 
1) VO2peak obtained from the RGAP via a metabolic cart, 2) estimated VO2peak calculated 
from the last completed stage of the GA test using ACSM’s walking/running equations 





RWOGAP.  VO2peak values from the GA test were compared with VO2peak that was 
calculated from the last stage of the same test to determine whether the ACSM equations 
were valid in determining VO2peak.  The values from the BTP and GA were compared to 
determine whether the BTP yielded accurate values for CS.  Finally, the GA values were 
compared to the values calculated from a separate RMCRI test without GA to determine 
whether the metabolic cart altered a cancer survivor’s performance on a treadmill test.     
Rocky Mountain Cancer Rehabilitation  
Institute Protocol 
 
 The RMCRI treadmill protocol appears in detail in Table 1 and in Appendix F.  
There are 21 total stages, with each being only one minute long.  Stage zero starts at 1 
mph and a 0% incline.  Speed will increase by no more than 0.5 mph from stage zero to 
stage six, and an incline of 2% will not be seen until stage four.  Starting at stage six, 
speed will increase by 0.1 mph and grade will increase by 1% after every completed 
stage.  Participants were explained that they will be performing a RMCRI VO2peak 
treadmill test and that they may end the test whenever they deem necessary, but are 























Rocky Mountain Cancer  
Rehabilitation Protocol 
Stage Speed Grade Time 
0 1.0 mph 0% 1 min 
1 1.5 mph 0% 1 min 
2 2.0 mph 0% 1 min 
3 2.5 mph 0% 1 min 
4 2.5 mph 2% 1 min 
5 3.0 mph 2% 1 min 
6 3.3 mph 3% 1 min 
7 3.4 mph 4% 1 min 
8 3.5 mph 5% 1 min 
9 3.6 mph 6% 1 min 
10 3.7 mph 7% 1 min 
11 3.8 mph 8% 1 min 
12 3.9 mph 9% 1 min 
13 4.0 mph 10% 1 min 
14 4.1 mph 11% 1 min 
15 4.2 mph 12% 1 min 
16 4.3 mph 13% 1 min 
17 4.4 mph 14% 1 min 
18 4.5 mph 15% 1 min 
19 4.6 mph 16% 1 min 
20 4.7 mph 17% 1 min 






During the test, heart rate and SpO2 were taken at the end of every minute.  RPE and BP 
were taken at the end of every three minutes.  Clients were encouraged to not use the 
handrails during the test, but if they felt uncomfortable or felt that the handrails are 
necessary then they were allowed.  The test ended when the participant felt he or she had 
reached their maximum threshold of exertion on the treadmill and could not continue any 
further.  The test also ended if any of the following criteria were met: HR did not increase 
with increased intensity, systolic blood pressure (SBP) did not increase with intensity, 
DBP oscillated more than 10 mmHg from resting measure, SpO2 dropped below 80%, 
and/or verbal consent of the participant to end the test due to any safety issues.   
Once the client reached his or her perceived maximal exertion, a cool down 
period was given in order for the client to return close to their resting measures.  During 
the cool down, HR and SpO2 were taken every minute, and RPE and BP was taken once 
every three minutes.  Once values reached close to resting measures, and the client felt 
comfortable to get off the treadmill, the treadmill was stopped.  Final HR was taken at the 
conclusion of the test, along with the time of duration and final completed stage.  
American College of Sport Medicine walking and running equations were used to 
calculate VO2peak by using the last completed stage of the protocol.  If the participant was 
walking at the termination point of the test, the following equation was used: VO2peak= 
(0.1 x S) + (1.8 x S x G) + 3.5.  The variable S represents the speed of the treadmill 
expressed in meters/min, and G signifies the grade of the treadmill expressed in decimal 
format (%).  Depending on how far a participant goes, the individual may be walking or 
running due to the speed and/or grade.  The subject will determine whether they need to 





walking at the termination of the test, the following correction equation was used: 
VO2peak = 0.694 [(0.1 x S) + (1.8 x S x G) + 3.5] + 3.33.  If the subject was running when 
the test was terminated, the following equation was used: VO2peak = (0.2 x S) + (0.9 x S x 
G) + 3.5.  If the subject was running at the end of the test while holding on to the 
handrails the following correction equation was used:  VO2peak =0.694 [(0.2 x S) + (0.9 x 
S x G) + 3.5] + 3.33 (American College of Sports Medicine, 2013).   
Bruce Protocol 
 
The BTP is shown in Table 2 and in Appendix G.  This protocol consists of a 
three minute warm-up at 1.7 mph at a 0% grade, followed by seven different three minute 
stages where both the speed and grade will be increased at the completion of each stage.  
The first stage starts at 1.7 mph and 10% grade, where grade then increases by 2% every 
stage and speed increases from 0.5-0.9 mph, depending on the stage.  Handrail usage 
criteria was identical to the RMCRI protocol guidelines.  Each participant started with a 
three minute warm-up at a low intensity with 0% grade.  Once the test began, HR, BP, 
and RPE were taken once every three minutes.  The participant was instructed to go as far 
as he or she possibly could, exerting themselves to perceived maximum effort.  
Termination criteria was exactly the same as the RMCRI protocol.  After exhaustion was 
achieved, a cool-down period was initiated.  During this time, RPE, SpO2, blood 
pressure, and HR were taken once every three minutes.  Once the client’s HR and RPE 
measures were close to resting values, the treadmill was stopped.  Final time, HR, blood 
pressure, and RPE were recorded.  To calculate VO2peak, the Bruce active and sedentary 
men and women generalized equations were used.  If the subject was male, the following 
equation will be utilized: VO2peak = 14.76 – 1.379 (time) + 0.451 (time





If the participant was female, the following equation was used: VO2peak = 4.38 (time) – 
3.90.   
Table 2 
 




















































































































Rocky Mountain Cancer Rehabilitation Institute  
Protocol Gas Analysis 
 
 Gas analysis has been deemed the gold standard and most accurate method in 
determining VO2peak (Crouter, Antczak, Hudak, DellaValle, & Haas, 2006; Bassett Jr. et 
al., 2001).  Handrail usage and the treadmill protocol that was used for GA was identical 





Colorado Springs, CO.) was a 35 Series Data Acquisition System research grade 
metabolic cart, and has been used in over 30 years of research studies (Connolly & 
Hosking, 2005; Fatouleh & Macefield, 2011; Sealey, Leicht, Spinks, & Sinclair, 2010; 
Connolly, 2011; Guner et al., 2007; Matsui, Hattori, Takase, & Ishihara, 2006; Hirakawa, 
Oikawa, Bishop, & Hayashida, 2003; Liu, Li, Zeng, Zhong, & Chen, 2013).   Before each 
test, the metabolic cart was calibrated.  Oxygen (O2) and carbon dioxide (CO2) 
transducers were used.  The carbon dioxide transducer was calibrated using two gas 
samples with known CO2 concentrations.  The first was room air, which has a CO2 
content of 0.03% (atmospheric CO2).  The second gas had a CO2 content of 4.99% CO2.  
The oxygen transducer was calibrated using two gases of known composition and with 
oxygen concentrations appropriate to the range of measurements that were expected.  
Room air was used for one of the gases.  This has an O2 content of 21%.  A second 
concentration of 12.01% was used to represent an intermediate O2 concentration.  
Balanced nitrogen was also used.   
The flow head of the metabolic cart was utilized along with a spirometer flow 
head, which are precision differential pressure transducers for measuring variables such 
as inspiration and expiration flows.  It measured differential pressure across fine gauze 
mounted in the flow head.  The spirometer was calibrated to read in terms of flow (L/s), 
which was accomplished by injecting a known volume of air through the breathing circuit 
and integrating the flow signal in LabChart.  A 3-liter MLA5530 calibration syringe was 
used for this purpose and simulated a single expiration.  The plunger of the syringe was 
depressed at a steady rate, neither too quickly nor too slowly, and the plunger did not 





  Before the test began, each subject received a detailed explanation as to how and 
why the metabolic cart was being used.  The respiration mask was then attached to the 
subject’s face and held in place by Velcro straps.  A tube was then connected to the 
respiration mask to the metabolic cart.  Participants were instructed to try and breathe 
primarily through their mouths, not their noses.  A total of four CES’s were used for each 
metabolic cart test to ensure safety.  One was responsible for changing the speed and 
grade of the protocol.  A second recorded HR and RPE every minute, as well as 
termination time.  The respiration mask made the participant inaudible, so they were 
instructed to give RPE using their fingers (ex. two fingers up = RPE of a two).  A third 
stood behind the treadmill and be available for spotting purposes, and a final one set up 
and ran the metabolic cart during the test.  Due to the metabolic cart, the CES was able to 
directly see what the subject’s true VO2 was at any given moment.  Additionally, VO2 
was plotted on a graph in real-time to make the highest VO2 value easily distinguishable.  
Participants were encouraged to push themselves to what they perceived as their maximal 
effort.  Termination criteria was identical to the RMCRI protocol.  If any of these 
criterion were met, the subject entered a cool-down period.  Heart rate and RPE were 
measured every minute until resting measures were achieved.  Also, RER, O2, and CO2 
were recorded every ten seconds and when they returned to resting measures, the 
treadmill was deemed safe to stop.  VO2peak was determined by taking the highest VO2 
value that was observed during the test.  This value was recorded in liters per minute 
(L/min).  To convert this to mL·kg-1·min-1, the following equation was used: [(L/min x 





running equations using the last completed stage during the GA test.  This value was then 
compared to the value obtained via GA. 
Pilot Study 
 
 To assess the feasibility and tolerance to these protocols, a pilot study was 
performed in which ten CS completed all three protocols.  These were CS who were 
participants in RMCRI’s rehabilitation program.  The tests and procedures were 
explained exactly as described above.  These subjects completed all protocols over three 
weeks, with a week of rest following each completed test.  A one week increment was 
chosen as this is the standard time allotted for recovery and rest between initial 
assessments and entry into the standard RMCRI program.  Deconditioning was also 
unlikely during this time as subjects were continuing low-to-moderate exercise sessions 
in between each test.  Initial HR, RPE, SpO2, BP, and body weight were recorded.  
Testing and termination criteria were identical to the procedures listed in the RMCRI 
protocol. Using the statistical analysis Friedman’s test, no significant differences in 
VO2peak were observed between the BTP, GA, or RMCRI protocol (p = 0.19).  The mean 
VO2peak was 26 + 7 mL·kg
-1·min-1; a moderate correlation was observed between the BTP 
and metabolic cart values (r = 0.63), and a strong correlation was witnessed between GA 
and RMCRI VO2peak values (r = 0.93).   No adverse side effects were observed in any of 
the ten subjects after the completion of the tests.  Additionally, because no differences 
were found in VO2peak, a training effect was not to be expected.  Although the GA and 
BTP caused some discomfort, all protocols were tolerated. It should be noted that when 
all participants were asked which protocol they felt was the most appropriate given their 







 A power analysis was run using the statistical program G-Power (version 3.1) 
prior to the start of the study to determine appropriate sample sizes.  Effect sizes, which 
are descriptive statistics that convey the practical significance of results, were 
determined.  Using the differences and the standard deviations between the observations, 
a medium effect size was used for the cancer survivor subjects with a level confidence of 
95%.  For the control participants, a large effect size with a level confidence of 95% was 
used due to a smaller sample size.  For both groups, a repeated measures ANOVA was 
utilized to examine differences in VO2peak values determined by RGAP, EVACSM, 
VO2peak determined by generalized prediction VO2peak equations following a BTP, and 
RWOGAP.  Assumptions included 1) the dependent variable (VO2peak) was continuous, 
2) the independent variable (treadmill protocols) were matched pairs, 3) there were no 
significant outliers in the related groups, and 4) the distribution of the dependent variable 
was approximately normally distributed.  Post-hoc Tukey pair-wise comparisons were 
run on any statistical data requiring follow-up analyses.  An unpaired t-test was utilized 
to examine differences between the AH in CS group in age, weight, RHR, RSBP, and 
RDBP. 
A Pearson-r correlation was run to determine the strength of relationship for 
VO2peak for both the cancer survivor group and the control group between RGAP and 
RWOGAP, VO2peak from RGAP and EVACSM, and RGAP and generalized prediction 
VO2peak equations via a BTP for the CS.  Statistical analyses was performed using the 





Significance levels were set at p < 0.05 and a Pearson correlation coefficient r > 0.80 











 The purpose of this study was to assess construct validity of the RMCRI multi-
stage treadmill protocol for a cancer-specific population against standard metabolic gas 
analysis and the Bruce treadmill protocol. 
Participant Characteristics 
Table 3 displays cancer types of the CS.  Tables 4 and 5 display gender and 
resting characteristics of all participants, respectively.  The AH group was comprised of 
eight males and eight females, with a mean age of 46 ± 13 years of age and mean weight 
of 72 ± 20.9 kilograms (kg).  The average resting heart rate (RHR), systolic blood 
pressure (RSBP), and diastolic blood pressure (RDBP) was 79 ± 15 bpm, 116 ± 9 mmHg, 
and 77 ± 9 mmHg, respectively.  There were no significant differences observed between 
RHR (p = 0.68), RSBP (p = 0.21), and RDBP (p = 0.45) among the AH group.  Of the 
AH subjects, 9 (56%) participants previously underwent surgery, but those surgeries were 
unrelated to cancer. 
The CS group consisted of 36 females and nine males with a mean age of 61.0 ± 
12 years and a mean weight of 75 ± 14 kg.  RHR, RSBP, and RDBP were 83 ± 15 bpm, 
122 ± 13 mmHg, and 75 ± 13 mmHg, respectively.  No significant differences were 
observed between RHR (p = 0.96), RSBP (p = 0.30), and RDBP (p = 0.39) prior to the 





participants (4%) underwent radiation only, six participants (13%) underwent surgery and 
radiation treatments, one participant (2%) underwent radiation and chemotherapy, 
nineparticipants (20%) underwent surgery and chemotherapy, and 15 participants (34%) 
underwent surgery, chemotherapy, and radiation.  All participants completed each 
VO2peak assessment without complications. 
There were no significant differences observed in weight (p = 0.81), RHR (p = 
0.55), RSBP (p = 0.06), and RDBP (p = 0.87) between the CS and AH groups.  The CS 





























Table 4  
 
Gender Characteristics 
  Males Females 
Cancer Survivors 9 36 
Control Subjects 8 8 





Age, Weight, and Resting Characteristics 
 
Cancer Survivors        Control Subjects P-Value 
Age 61 ± 12 49 ± 14 0.006 
Weight (kg) 75 ± 14 72 ± 21 0.81 
RHR 83 ± 15 79 ± 15 0.55 
RSBP 122 ± 13 116 ± 9 0.06 
RDBP 75 ± 13 77 ± 9 0.87 
 





Table 6  
 
Mean Peak Exercise Values 
 RGAP EVACSM BTP RWOGAP P-Value 
Cancer Survivors  
HR 159.0 ± 17.0  -  152.0 ± 20.0 157.0 ± 19.0 <0.05δ† 
SBP 150.0 ± 14.0  -  150.0 ± 14.0 152.0 ± 13.0 0.31 
DBP 76.0 ± 19.0  -  78.0 ± 9.0 79.0 ± 8.0 0.76 
RPE 9.0 ± 1.0  -  9.0 ± 1.0 9.0 ± 1.0 0.2 
RER 0.9 ± 0.1  -        - 
Treadmill time (min) 12.1 ± 2.8  -  8.1 ± 2.3 12.6 ± 3.0 <0.05*δ† 
VO2 (mL•kg-
1•min-1) 26.8 ± 7.0 26.2 ± 6.5 29.2 ± 8.1 27.1 ± 6.5 <0.05δ† 
VO2 (L/min) 1.9 ± 0.4 1.9 ± 0.8 2.2 ± 0.7 2.0 ± 0.8 <0.05δ† 
VO2 (METS) 7.6 ± 2.0 7.4 ± 2.2 8.3 ± 2.3 7.7 ± 1.8 <0.05δ† 
              
Control Subjects              
HR 171.0 ± 16.0  -  174.0 ± 16.0 177.0 ± 12.0 0.673 
SBP 152.0 ± 18  -  155.0 ± 23.0 152.0 ± 13.0 0.846 
DBP 81.0 ± 8.0  -  78.0 ± 12.0 82.0 ± 10.0 0.451 
RPE 9.0 ± 1.0  -  9.0 ± 1.0 9.0 ± 1.0 0.204 
RER 1.1 ± 0.1  -         - 
Treadmill time 16.4 ± 3.8  -  10.6 ± 2.7 16.6 ± 3.6 <0.05δ† 
VO2 (mL•kg-
1•min-1) 38.3 ± 16.7 38.3 ± 8.4 39.8 ± 10.6 38.7 ± 7.3 0.724 
VO2 (L/min) 2.7 ± 1.0 2.7 ± 1.0 2.8 ± 0.8 2.7 ± 0.8 0.692 
VO2 (METS) 10.3 ± 4.0 10.3 ± 2.4 10.1 ± 4.6 10.4 ± 3.3 0.766 
 
Note: HR = heart rate; SBP = systolic blood pressure; DBP = diastolic blood pressure; RPE = rating of perceived exertion; RER = 
respiratory exchange ratio; * denotes a p value < 0.05 RGAP vs. RWOGAP, δ denotes a p value < 0.05 RGAP vs. BTP; † denotes a 







Validity of Peak Volume of Oxygen Consumption 
 Assessments for the Apparently Healthy  
Control Participants 
 
 Table 6 depicts average peak treadmill variables.  Criteria to be classified as a 
VO2peak test were met 100% of the time.  There were no significant differences between 
average peak HR (p = 0.67), SBP (p = 0.85), DBP (p = 0.45), and RPE (p = 0.20) values 
between any of the protocols.  Figure 1 displays mean VO2peak values (mL·kg
-1·min-1) for 
the AH subjects.  There were no significant differences in the average VO2peak (mL·kg
-
1·min-1) between the RGAP (38.3 ± 16.7), EVACSM (38.3 ± 8.4), BTP (39.8 ± 10.6), or 
RWOGAP (38.7 ± 7.3) (p = 0.72).  No significant differences were observed in average 
VO2peak (L/min) between RGAP (2.7 ± 1.1), EVACSM (2.7 ± 0.8), BTP (2.8 ± 0.8), or 
RWOGAP (2.7 ± 0.8) (p = 0.69).  There were no significant differences in average peak 
MET values between RMCRI gas analysis protocol (10.3 ± 4.8), estimated VO2peak using 
the last completed stage of RGAP using ACSM’s walking and running equations,  (10.3 
± 2.4), BTP (10.1 ± 4.6), or Rocky Mountain Cancer Rehabilitation Institute without gas 
analysis protocol (10.4 ± 3.3) (p = 0.77).  Average total peak treadmill time observed was 
significantly greater during RGAP (16.4 ± 3.8 min) than BTP (10.6 ± 2.7 min) (p = 
0.001), and RWOGAP average treadmill time (16.69 ± 3.66 min) was significantly 
greater compared to total time on the BTP (p = 0.001).  Average peak RER was 
attainable only via GA, and was 1.19 ± 0.09.   
Validity of Peak Volume of Oxygen Consumption 
 Assessments for Cancer Survivors 
 
 Table 6 depicts average peak treadmill variables.  Criteria to be classified as a 
VO2peak test were met 100% of the time.   There were no significant differences in peak 




perceived exertion (p = 0.20) values. Average peak HR was significantly lower in BTP 
(151.9 ± 19.7) when compared to both RGAP (158.9 ± 16.7) (p = 0.01) and RWOGAP 
(156.9 ± 19.1) (p = 0.01).  Figure 2 displays mean VO2peak values for CS.  VO2peak values 
were significantly lower for RGAP than the BTP (26.8 ± 7.0 vs. 29.2 ± 8.0, respectively) 
(p = 0.01), significantly lower in RWOGAP compared to the BTP value (27.1 ± 6.5 vs. 
29.2 ± 8.0, respectively) (p = 0.01), and the EVACSM was significantly lower compared 
to BTP (26.2 ± 6.5 vs. 29.2 ± 8.0, respectively) (p = 0.01).  The Bruce treadmill protocol 
had significantly higher achieved METS compared to Rocky Mountain Cancer 
Rehabilitation Institute gas analysis protocol (8.3 ± 2.3 vs. 7.6 ± 2.0, respectively) (p = 
0.03), as well as significantly higher achieved METS compared to RWOGAP (8.3 ± 2.3 
vs. 7.7 ± 1.8, respectively) (p = 0.03).  VO2peak (L/min) was significantly greater in BTP 
compared to RGAP (2.20 ± 0.78 vs. 1.9 ± 0.4, respectively) (p = 0.009), and significantly 
higher in the BTP compared to RWOGAP (2.20 ± 0.78 vs. 2.0 ± 0.8, respectively) (p = 
0.009).  Total treadmill time was significantly higher on RGAP (12.1 ± 2.8) compared to 
total time on the BTP (8.1 ± 2.3) (p = 0.001), significantly higher on RWOGAP 
compared to the BTP (12.6 ± 3.0 vs. 8.1 ± 2.3, respectively) (p = 0.001), and 
significantly higher on RWOGAP compared to RGAP (12.6 ± 3.0 vs. 12.1 ± 2.8, 
respectively) (p = 0.01).  Average peak respiratory exchange ratio was attainable only via 
GA, and was 0.9 ± 0.1. 
Correlation Analyses 
Figures 3-5 display correlations for the apparently healthy group.  Positive strong 
correlations were observed between RGAP and EVACSM (r = 0.90), the BTP and RPGA 




group are seen in Figures 6-8.  There were strong positive correlations observed between 
the VO2peak obtained from RGAP and from EVACSM (r = 0.90) and between VO2peak 
from RGAP and RWOGAP (r = 0.81).  There was a moderate, positive correlation 
between RGAP VO2peak and the BTP VO2peak (r = 0.51). 
   
Figure 1.  Mean VO2peak values for Apparently Healthy Control Group.  RGAP, RMCRI 
gas analysis protocol; EVACSM, estimated VO2peak calculated from the last completed 
stage of the GA test using ACSM’s walking/running equations; BTP, Bruce treadmill 
protocol; RWOGAP, RMCRI without gas analysis protocol.  Data are mean + SD 
 
 
Figure 2. Mean VO2peaks for Cancer Survivor Group.  RGAP, RMCRI gas analysis 
protocol; EVACSM, estimated VO2peak calculated from the last completed stage of the 
GA test using ACSM’s walking/running equations; BTP, Bruce treadmill protocol; 
RWOGAP, RMCRI without gas analysis protocol. †p < 0.05 RGAP vs. Bruce value; δp < 
























































Figure 3. AH correlation between RGAP VO2peak and EVACSM 
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Figure 5. AH correlation between RGAP VO2peak and Bruce VO2peak Protocol 
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Figure 7. CS correlation between RGAP VO2peak and RWOGAP VO2peak 
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The statistical analysis repeated measures ANOVA test was confirmed to be an 
appropriate test to compare VO2peak values.  The dependent variable (VO2peak) was a 
continuous value, the independent variables (RGAP, BTP, and RWOGAP) were all 
matched pairs, and there were no significant outliers in the related groups.  Additionally, 
the VO2peak values were plotted on a histogram to illustrate the distribution of all VO2peak 
points.  From this histogram, the dependent variable appeared to be approximately 
normally distributed.  Due to all assumptions being met, along with the normal 
distribution of the data, the repeated measures ANOVA was the appropriate statistical 










 Today there are approximately 13.7 million Americans living with a history of 
cancer, and over 1.6 million new diagnoses of cancer are expected this year (ACS, 2015).  
This year, more than half a million of Americans are expected to succumb to this disease, 
as it is the second leading cause of death (ACS, 2015).  Fortunately, due to recent 
advancements in cancer treatments and diagnoses, the 5-year survival rate for cancer is 
now at 68%.  The increased survival rate may, consequently, result in many cancer 
survivors suffering from deleterious side effects of cancer and cancer treatments.  Due to 
these side effects, cancer rehabilitation programs are being implemented to combat these 
symptoms through prescriptive exercise interventions.  The goal of these programs is to 
improve cancer survivors’ functional capacity as well as their psychosocial well-being 
(Schmitz et al., 2010).  
It has been demonstrated that physical activity performed before, during, and after 
cancer treatment plays an instrumental role in improving physiological and psychological 
factors, such as increased maximal oxygen consumption (VO2max) and quality of life 
(QOL) (Anderson et al., 2010; Groeneveldt et al., 2013).  VO2max is considered the best 
indicator of overall health and is most accurately obtained via a metabolic cart utilizing 




cancer mortality (Gulati et al., 2003; Myers et al., 2002; Sawada et al., 2003).  This 
stresses the importance of establishing an accurate VO2max for cancer survivors when 
designing a rehabilitative exercise intervention.  Although VO2max is considered to be the 
best measure of aerobic capacity, VO2peak is often used with special populations due to the 
inability of achieving VO2max criteria and has been shown to be as accurate VO2max (Day 
et al., 2003; Howley, 2007; Jones et al., 2011; Kim et al., 2006).   
 Graded exercise tests are normally performed by cancer survivors to determine 
VO2peak and exercise capacity, allowing clinicians to form a more accurate prescription of 
exercise for rehabilitation.  Treadmill running/walking and cycle ergometry are the most 
commonly used modalities for VO2 tests, but treadmill protocols have been reported to 
elicit higher and more accurate VO2peak values than cycle ergometry protocols (Moody et 
al., 1969; Pollock et al., 1982; Astrand & Rodahl, 1977).  The Bruce treadmill protocol 
(BTP), which is used by more than half of the clinicians in North America (Chugh, 2012; 
Hill & Timmis, 2002; Marinov et al., 2002; Stuart & Ellestad, 1980), is highly correlated 
with VO2peak and is considered to be one of the most accurate predictors of 
cardiorespiratory fitness.  This protocol however, elicits increased workload via large 
increases in speed and incline with each stage, which may result in inaccurate VO2peak 
values (Cunha et al., 2012; Foster et al., 1984; Lee et al., 2011; Redwood, Rosing, 
Goldstein, & Epstein, 1971; Sullivan & McKirnan, 1984;).  Furthermore, protocols that 
have large single-stage increases in exercise intensity may be unsuitable for cancer 
survivors and may result in inaccurate measurements of VO2peak.  
 Currently a cancer-specific treadmill protocol does not exist.  To address this 




RMCRI multi-stage treadmill protocol for the measurement of VO2peak in the cancer 
population.  This protocol is designed to increase speed and grade in minimal increments 
with shorter stages providing a more gradual increase in intensity.  This slowed 
progression of intensity may be perceived as less intimidating for cancer survivors, unlike 
the sudden, large increases in intensity with the BTP (Bader, Maguire, & Balady, 1999; 
Will & Walter, 1999).  Specifically, cancer survivors who are suffering from cancer and 
cancer-related toxicities may be better able to tolerate the lower intensities associated 
with the RMCRI protocol, allowing the patients to exercise longer, thereby establishing a 
more accurate VO2peak value.  This allows Cancer Exercise Specialists (CES) the ability to 
form an accurate prescription of exercise and a subsequent exercise intervention.   
With the increase in survival rates, cancer rehabilitation programs are serving an 
integral role in assisting patients in recovery and regaining health.  Establishing an 
accurate VO2peak value and baseline measure of cardiorespiratory endurance is the first 
and foremost step in this process.  This demonstrates the need to validate the 
effectiveness of a cancer-specific protocol.  Therefore, the purpose of this study was to 
assess the construct validity of the RMCRI multi-stage treadmill protocol in a cancer-
specific population against standard metabolic GA and the standard BTP. 
Methods 
Subjects 
Participants were enrolled in the study upon completion of a medical history form 
and after signing an informed consent approved by the University of Northern Colorado’s 
Institutional Review Board (Appendix D).  A total of 61 subjects participated.  




Mountain Cancer Rehabilitation Institute’s (RMCRI) cancer rehabilitation program.  
Apparently healthy (AH) control subjects (n = 16) were recruited from the University of 
Northern Colorado (UNC) campus through recruitment fliers distributed via email.  
Participants were excluded if they had a history of congestive heart failure, a history of 
myocardial infarction, chronic lung disease, asthma, significant ambulatory issues, 
history of coughing up blood, a history of fainting, epilepsy, and/or neuropathy in the 
lower extremities.   
Experimental Design 
Participants who qualified for the study completed three separate treadmill 
protocols over the course of three weeks.  The order of completion was determined by 
random assignment using the Statistical Analysis System (SAS) PROC PLAN 
randomization procedure (SAS, 9.3).  A week of rest following each treadmill test was 
given to allow subjects to recover and reduce the risk of fatigue.  The following protocols 
were performed: RMCRI VO2peak gas analysis protocol (RGAP), VO2peak Bruce treadmill 
protocol (BTP), and RMCRI VO2peak without GA protocol (RWOGAP).  Resting blood 
pressure (BP), heart rate (HR), and blood oxygen saturation (SpO2) were measured before 
all tests, along with the subject’s body weight.  BP was determined using manual 
auscultation via a blood pressure cuff and stethoscope, heart rate was determined using a 
Polar® heart rate monitor, and SpO2 was determined using a Clinical Guard
® pulse 
oximeter.  During all tests, SpO2 and HR were recorded once every minute, and rating of 
perceived exertion (RPE) and BP were recorded every three minutes.  Depending upon 
the protocol, three to four Cancer Exercise Specialists (CES) conducted all treadmill tests 




the treadmill and recording all information during the test, a second measured BP, a third 
stood behind the treadmill to spot the subject, and a fourth set up and operated a 
metabolic cart, when necessary.   
For all tests, subjects were encouraged to refrain from using the handrails during 
the test, but if it was deemed necessary due to subject discomfort or increased risk, they 
held onto the handrails.  The tests terminated when the participant felt they reached their 
maximum threshold of exertion on the treadmill and could not continue any further.  The 
tests would also conclude if any of the following criteria were met:  HR did not increase 
with increased intensity, systolic blood pressure (SBP) did not increase with intensity, 
DBP oscillated more than 10 mmHg from resting measure, SpO2 dropped below 80%, 
and/or verbal consent of the participant to end the test due to any safety issues.  A cool 
down period was conducted after completion of the test to ensure that the subject returned 
to their near resting vital measures.  Final HR, BP, SpO2, and treadmill time were 
recorded. 
Before each test begins, the participants will be given the following instructions: 
1) one CES will be taking your blood pressure once every three minutes, 2) another CES 
will be recording all data from the test, as well as changing the speed and grades of the 
treadmill, 3) a pulse oximeter will be placed on your index finger, in which we will 
record your oxygen saturation at the end of every minute, 4) another CES will be 
standing behind the treadmill for spotting purposes, 5) we would like you to push 
yourself to what you feel is your maximum exertion; you may stop the test at any point, 
but we would like you to reach the point where you feel you cannot physically continue, 




regardless whether you choose to use or not to use handrails, you must choose one for the 
entire duration of the test, you may not go back and forth, and 7) once you reach 
perceived maximal exertion, we will begin a cool-down to lower your vitals close to 
resting measures.   
A test was deemed a VO2peak test if at least two of the following criteria were met:  
1) subject terminated test due to perceived maximal effort and fatigue, 2) heart rate was 
elevated to within ten beats per minute of the individual’s estimated heart rate max, and 
3) if a subject gave a RPE value on the modified Borg RPE scale of at least an eight.  If at 
least two of these criterions were not met, the test results were not used.  Four different 
values were compared using a repeated measures ANOVA test: 1) VO2peak obtained from 
RGAP, 2) estimated VO2peak from the last completed stage of the GA test using ACSM’s 
walking/running equations (EVACSM), 3) VO2peak peak from a peak BTP, and (4) 
VO2peak calculated from RWOGAP.  VO2peak values from the RGAP test were compared 
with EVACSM to determine whether the ACSM equations were valid in determining 
VO2peak.  Values from BTP and RGAP were compared to determine whether BTP yields 
accurate values for cancer survivors.  Finally, the RGAP values were compared to the 
values from RWOGAP to determine whether the metabolic cart may alter a cancer 
survivor’s performance on a treadmill test.     
Rocky Mountain Cancer Rehabilitation  
Institute Protocol 
 
 This protocol consisted of 21 stages, with each being only one minute long.  
Speed and/or grade were increased at the completion of each stage.  Details of this 




performing a RMCRI VO2peak treadmill test and that they could end the test whenever 
they deemed necessary, but were encouraged to continue as far as physically possible.   
ACSM walking and running equations were used to calculate VO2peak by using the 
last completed stage of the protocol.  The subject determined whether he or she needed to 
walk or run at the last completed stage.  If the subject was walking when the test was 
terminated, the following equation was used:  VO2peak = (0.1 x S) + (1.8 x S x G) + 3.5; 
where S = speed and G = grade.  If a subject was holding onto the handrails and walking 
at the termination of the test, the following correction equation was used: VO2peak = 0.694 
[(0.1 x S) + (1.8 x S x G) + 3.5] + 3.33.  If the subject was running when the test was 
terminated, the following equation was used: VO2peak = (0.2 x S) + (0.9 x S x G) + 3.5.  If 
the subject was running at the end of the test while holding on to the handrails the 
following correction equation was used:  VO2peak = 0.694 [(0.2 x S) + (0.9 x S x G) + 3.5] 


























Rocky Mountain Cancer Rehabilitation  
Institute Protocol  
 
Stage Speed Grade Time 
0 1.0 mph 0% 1 min 
1 1.5 mph 0% 1 min 
2 2.0 mph 0% 1 min 
3 2.5 mph 0% 1 min 
4 2.5 mph 2% 1 min 
5 3.0 mph 2% 1 min 
6 3.3 mph 3% 1 min 
7 3.4 mph 4% 1 min 
8 3.5 mph 5% 1 min 
9 3.6 mph 6% 1 min 
10 3.7 mph 7% 1 min 
11 3.8 mph 8% 1 min 
12 3.9 mph 9% 1 min 
13 4.0 mph 10% 1 min 
14 4.1 mph 11% 1 min 
15 4.2 mph 12% 1 min 
16 4.3 mph 13% 1 min 
17 4.4 mph 14% 1 min 
18 4.5 mph 15% 1 min 
19 4.6 mph 16% 1 min 
20 4.7 mph 17% 1 min 








 This protocol consists of seven stages which increase speed and grade in three 
minute increments.  To calculate VO2peak, the Bruce active and sedentary men and women 
generalized equations were used.  If the subject was male, the following equation was 
utilized:  VO2peak = 14.76 – 1.379 (time) + 0.451 (time
2) – 0.012 (time3).  If the 
participant used handrails, the following equation was used: VO2peak = 0.694 [14.76 – 
1.379 (time) + 0.451 (time2) – 0.012 (time3)] + 3.33.   If the participant was female, the 
following equation was used:  VO2peak = 4.38 (time) – 3.90.  If the participant used 
handrails, the following equation was used: VO2peak = 0.694 [4.38 (time) – 3.90] + 3.33. 
Rocky Mountain Cancer Rehabilitation  
Institute Gas Analysis 
 
  Using a 35 Series Data Acquisition System research grade metabolic cart 
(ADInstruments, Colorado Springs, CO), expired gases were continuously collected 
where VO2 and VCO2 were recorded once every 10 seconds.  Calibration of the metabolic 
cart was performed before each test with a 3 L syringe and precision gas mixtures.  
Before the test began, each subject received a detailed explanation as to how the test was 
conducted, and why the metabolic cart was being used.  A respiration mask was attached 
to the subject’s face and held in place by Velcro® straps.  A tube connected the 
respiration mask to the metabolic cart.  Participants were instructed to breathe primarily 
through their mouths, not their noses.  The respiration mask made the participant 
inaudible, so participants were instructed to give RPE using their fingers (for example, 
two fingers up = RPE of two).  In addition to standard termination criteria, this protocol 




If any of these criteria were met, the test was terminated and the subject began a cool-
down period.  VO2peak was determined by taking the highest VO2 value that was observed 
during the test and was recorded in liters per minute (L/min).  To convert this to mL·kg-
1·min-1, the following equation was used:  [(L/min x 1000)/body weight (kg)].  
Additionally, VO2peak was calculated via ACSM’s walking and running equations using 
the last completed stage during the GA test.  This value was then compared to the value 
obtained via GA. 
Statistical Analysis 
 
 All data are presented as mean ± standard deviation (SD).  For the CS and AH 
group, a repeated measures ANOVA test was utilized to examine differences in VO2peak 
values via a RGAP, EVACSM, generalized prediction VO2peak equations following a 
BTP, and RWOGA.  Independent sample t-tests were conducted to determine any 
differences between the CS and AH group in age, weight, and resting vitals.  Post-hoc 
Tukey pair-wise comparisons were conducted on any statistical data requiring follow-up 
analyses.   
A Pearson r correlation was conducted to examine the strength of relationship in 
VO2peak for both the CS and AH group between RGAP and RWOGAP, VO2peak calculated 
from RGAP and EVACSM, and RGAP and generalized prediction VO2peak equations via 
a BTP for the cancer survivors.  Statistical analyses were performed using the Statistical 
Package for the Social Sciences software package (SPSS, Chicago, IL.).  Significance 
levels were set at p < 0.05 and a Pearson correlation coefficient r > 0.80 with GA will be 








Table 8 displays cancer types of the CS.  Tables 9 and 10 display gender and 
resting characteristics of all participants, respectively.  The AH group was comprised of 
eight males and eight females, with a mean age of 46 ± 13 years of age and mean weight 
of 72 ± 20.9 kilograms (kg).  The average resting heart rate (RHR), systolic blood 
pressure (RSBP), and diastolic blood pressure (RDBP) was 79 ± 15 bpm, 116 ± 9 mmHg, 
and 77 ± 9 mmHg, respectively.  There were no significant differences observed between 
RHR (p = 0.68), RSBP (p = 0.21), and RDBP (p = 0.45) among the apparently healthy 
group.  Of the AH subjects, 9 (56%) participants previously underwent surgery, but those 
surgeries were unrelated to cancer. 
The cancer survivor group consisted of 36 females and nine males with a mean 
age of 61.0 ± 12 years and a mean weight of 75 ± 14 kg.  Resting heart rate, resting 
systolic blood pressure, and resting diastolic blood pressure were 83 ± 15 bpm, 122 ± 13 
mmHg, and 75 ± 13 mmHg, respectively.  No significant differences were observed 
between RHR (p = 0.96), RSBP (p = 0.30), and RDBP (p = 0.39) prior to the three 
individual tests.  Of the CS, 12 participants (27%) underwent surgery only, two 
participants (4%) underwent radiation only, six participants (13%) underwent surgery and 
radiation treatments, one participant (2%) underwent radiation and chemotherapy, nine 
participants (20%) underwent surgery and chemotherapy, and 15 participants (34%) 
underwent surgery, chemotherapy, and radiation.  All participants completed each 




There were no significant differences observed in weight (p = 0.81), resting heart 
rate (p = 0.55), resting systolic blood pressure (p = 0.06), and resting diastolic blood 
pressure (p = 0.87) between the CS and AH groups.  The CS group was significantly 



































Cancer Survivors 9 36 
Control Subjects 8 8 






Age, Weight, and Resting 
Characteristics 
 
Cancer Survivors       Control Subjects P-Value 
Age 61 ± 12 49 ± 14 0.006 
Weight (kg) 74 ± 14 72 ± 21 0.81 
RHR 83 ± 15 79 ± 15 0.55 
RSBP 122 ± 13 116 ± 9 0.06 
RDBP 75 ± 13 77 ± 9 0.87 
 





Table 11  
 
Mean Peak Exercise Values 
 RGAP EVACSM BTP RWOGAP P-Value 
Cancer Survivors  
HR 159.0 ± 17.0  -  152.0 ± 20.0 157.0 ± 19.0 <0.05δ† 
SBP 150.0 ± 14.0  -  150.0 ± 14.0 152.0 ± 13.0 0.31 
DBP 76.0 ± 19.0  -  78.0 ± 9.0 79.0 ± 8.0 0.76 
RPE 9.0 ± 1.0  -  9.0 ± 1.0 9.0 ± 1.0 0.2 
RER 0.9 ± 0.1  -        - 
Treadmill time (min) 12.1 ± 2.8  -  8.1 ± 2.3 12.6 ± 3.0 <0.05*δ† 
VO2 (mL•kg-1•min-1) 26.8 ± 7.0 26.2 ± 6.5 29.2 ± 8.1 27.1 ± 6.5 <0.05δ† 
VO2 (L/min) 1.9 ± 0.4 1.9 ± 0.8 2.2 ± 0.7 2.0 ± 0.8 <0.05δ† 
VO2 (METS) 7.6 ± 2.0 7.4 ± 2.2 8.3 ± 2.3 7.7 ± 1.8 <0.05δ† 
              
Control Subjects              
HR 171.0 ± 16.0  -  174.0 ± 16.0 177.0 ± 12.0 0.673 
SBP 152.0 ± 18  -  155.0 ± 23.0 152.0 ± 13.0 0.846 
DBP 81.0 ± 8.0  -  78.0 ± 12.0 82.0 ± 10.0 0.451 
RPE 9.0 ± 1.0  -  9.0 ± 1.0 9.0 ± 1.0 0.204 
RER 1.1 ± 0.1  -        - 
Treadmill time 16.4 ± 3.8  -  10.6 ± 2.7 16.6 ± 3.6 <0.05δ† 
VO2 (mL•kg-1•min-1) 38.3 ± 16.7 38.3 ± 8.4 39.8 ± 10.6 38.7 ± 7.3 0.724 
VO2 (L/min) 2.7 ± 1.0 2.7 ± 1.0 2.8 ± 0.8 2.7 ± 0.8 0.692 
VO2 (METS) 10.3 ± 4.0 10.3 ± 2.4 10.1 ± 4.6 10.4 ± 3.3 0.766 
Note: HR = heart rate; SBP = systolic blood pressure; DBP = diastolic blood pressure; RPE = rating of perceived exertion, RER = 
respiratory exchange ratio; * denotes a p value < 0.05 RGAP vs. RWOGAP, δ denotes a p value < 0.05 RGAP vs. BTP; † denotes 








Validity of Peak Oxygen Consumption  
Assessments for the Apparently  
Healthy Control Participants 
 
 Table 11 depicts average peak treadmill variables.  Criteria to be classified as a 
VO2peak test were met 100% of the time.  There were no significant differences between 
average peak HR (p = 0.67), SBP (p = 0.85), DBP (p = 0.45), and RPE (p = 0.20) values 
between any of the protocols.  Figure 9 displays mean VO2peak values (mL·kg
-1·min-1) for 
the AH subjects.  There were no significant differences in the average VO2peak (mL·kg
-
1·min-1) between the RGAP (38.3 ± 16.7), EVACSM (38.3 ± 8.4), BTP (39.8 ± 10.6), or 
RWOGAP (38.7 ± 7.3) (p = 0.72).  No significant differences were observed in average 
VO2peak (L/min) between RGAP (2.7 ± 1.1), EVACSM (2.7 ± 0.8), BTP (2.8 ± 0.8), or 
RWOGAP (2.7 ± 0.8) (p = 0.69).  There were no significant differences in average peak 
MET values between Rocky Mountain Cancer Rehabilitation Institute Gas Analysis 
Protocol (10.3 ± 4.8), estimated VO2peak from last completed stage of RMCRI gas 
analysis protocol (10.3 ± 2.4), Bruce treadmill protocol (10.1 ± 4.6), or RMCRI without 
gas analysis protocol (10.4 ± 3.3) (p = 0.77).  Average total peak treadmill time observed 
was significantly greater during RGAP (16.4 ± 3.8 min) than BTP (10.6 ± 2.7 min) (p = 
0.001), and RWOGAP average treadmill time (16.69 ± 3.66 min) was significantly 
greater compared to total time on the BTP (p = 0.001).  Average peak RER was 
attainable only via GA, and was 1.19 ± 0.09.   
Validity of Peak Oxygen Consumption  
Assessments for Cancer Survivors 
 
 Table 11 depicts average peak treadmill variables.  Criteria to be classified as a 
VO2peak test were met 100% of the time.   There were no significant differences in peak 





perceived exertion (p = 0.20) values. Average peak HR was significantly lower in BTP 
(151.9 ± 19.7) when compared to both RGAP (158.9 ± 16.7) (p = 0.01) and RWOGAP 
(156.9 ± 19.1) (p = 0.01).  Figure 10 displays mean VO2peak values for the cancer 
survivors.  VO2peak values were significantly lower for RMCRI gas analysis protocol than 
the Bruce treadmill protocol (26.8 ± 7.0 vs. 29.2 ± 8.0, respectively) (p = 0.01), 
significantly lower in RWOGAP compared to the BTP value (27.1 ± 6.5 vs. 29.2 ± 8.0, 
respectively) (p = 0.01), and the EVACSM was significantly lower compared to BTP 
(26.2 ± 6.5 vs. 29.2 ± 8.0, respectively) (p = 0.01).  The Bruce treadmill protocol had 
significantly higher achieved METS compared to RGAP (8.3 ± 2.3 vs. 7.6 ± 2.0, 
respectively) (p = 0.03), as well as significantly higher achieved METS compared to 
RMCRI without gas analysis protocol (8.3 ± 2.3 vs. 7.7 ± 1.8, respectively) (p = 0.03).  
VO2peak (L/min) was significantly greater in the Bruce treadmill protocol compared to 
RMCRI gas analysis protocol (2.20 ± 0.78 vs. 1.9 ± 0.4, respectively) (p = 0.009), and 
significantly higher in the Bruce treadmill protocol compared to RMCRI without gas 
analysis protocol (2.20 ± 0.78 vs. 2.0 ± 0.8, respectively) (p = 0.009).  Total treadmill 
time was significantly higher on RGAP (12.1 ± 2.8) compared to total time on the BTP 
(8.1 ± 2.3) (p = 0.001), significantly higher on RWOGAP compared to the BTP (12.6 ± 
3.0 vs. 8.1 ± 2.3, respectively) (p = 0.001), and significantly higher on RWOGAP 
compared to RGAP (12.6 ± 3.0 vs. 12.1 ± 2.8, respectively) (p = 0.01).  Average peak 
respiratory exchange ratio was attainable only via GA, and was 0.9 ± 0.1. 
Correlation Analyses 
Figures 11-13 display correlations for the apparently healthy group.  Positive 





RPGA (r = 0.83), and RGAP and RWOGAP (r = 0.92).  Correlations for the cancer 
survivor group are seen in Figures 14-16.  There were strong positive correlations 
observed between the VO2peak obtained from RGAP and from EVACSM (r = 0.90) and 
between VO2peak from RGAP and RWOGAP (r = 0.81).  There was a moderate, positive 
correlation between RMCRI gas analysis protocol VO2peak and the Bruce treadmill 
protocol VO2peak (r = 0.51). 
 
Figure 9.  Mean VO2peak values for Apparently Healthy Control Group.  RGAP, RMCRI 
gas analysis protocol; EVACSM, estimated VO2peak calculated from the last completed 
stage of the GA test using ACSM’s walking/running equations; BTP, Bruce treadmill 


































Figure 10. Mean VO2peaks for Cancer Survivor Group.  RGAP, RMCRI gas analysis 
protocol; EVACSM, estimated VO2peak calculated from the last completed stage of the 
GA test using ACSM’s walking/running equations; BTP, Bruce treadmill protocol; 
RWOGAP, RMCRI without gas analysis protocol. †p < 0.05 RGAP vs. Bruce value; δp < 
0.05 Bruce value vs. RGAP. Data are means + SD.   
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Figure 12. AH correlation between RGAP VO2peak and RWOGAP VO2peak 
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Figure 14. CS correlation between RGAP VO2peak and EVACSM 
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Figure 16. CS correlation between RGAP VO2peak and Bruce VO2peak Protocol
 
The statistical analysis repeated measures ANOVA test was confirmed to be an 
appropriate test to compare VO2peak values.  The dependent variable (VO2peak) was a 
continuous value, the independent variables (RGAP, BTP, and RWOGAP) were all 
matched pairs, and there were no significant outliers in the related groups.  Additionally, 
the VO2peak values were plotted on a histogram to illustrate the distribution of all VO2peak 
points.  From this histogram, the dependent variable appeared to be approximately 
normally distributed.  Due to all assumptions being met, along with the normal 
distribution of the data, the repeated measures ANOVA was the appropriate statistical 
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 The aim of this study was to assess the validity of the RMCRI multi-stage 
treadmill protocol for a cancer-specific population against standard metabolic gas 
analysis and the Bruce treadmill protocol.  It was hypothesized that VO2peak obtained from 
RMCRI gas analysis protocol would not significantly differ from VO2peak calculated from 
the last completed stage of the GA test using ACSM’s walking and running equations.  
This was confirmed for the CS and AH groups with a strong, positive correlation of r = 
0.90 observed for both.  Similar correlations have also been reported between observed 
and predicted VO2peak values for current valid VO2peak protocols, such as the modified 
Balke treadmill test and the modified Naughton treadmill protocol (Ebbeling et al., 1991; 
Martin & Acker, 1988; Singh, Morgan, Hardman, Rowe, & Bardsley, 1994; Wolthuis et 
al., 1977).  Ramp protocols such as the RMCRI protocol demonstrate a positive linear 
relationship between oxygen uptake and work rate (Myers et al., 1991), which would 
explain the non-significant differences between meeasured and estimated VO2peak from 
the RGAP test.  These findings confirm that using ACSM’s walking and running 
equations are a valid method in determining VO2peak for the RMCRI protocol.  It also 
supports the notion that a metabolic cart is unnecessary to have during a cancer survivor’s 
VO2peak test if the ACSM equations produce accurate values that are not significantly 
different than those obtained through gas analysis.   
All participants were able to safely and effectively complete each VO2peak test, 
with no adverse effects experienced during or following a test.  Given the general 
compromised state of the cancer population, many facilities may opt for a submaximal 
protocol (Furzer et al., 2012; Jones et al., 2008).  However, the results of this study 





complications, while still obtaining an accurate VO2peak value.  Wall et al. (2014) reported 
similar results with prostate cancer survivors completing a VO2max treadmill test using a 
BTP.  In that study 85% of participants reached VO2max criteria without any adverse 
effects.  They concluded that the risk of detrimental events during maximal testing is 
relatively low and was no higher than what is observed in age-matched control 
participants.  Similarly, Scott et al. (2015) safely evaluated prostate cancer survivors 
using a modified Balke VO2max test.  In fact, 80% of the participants were able to 
complete two modified Balke VO2max tests within a week without injury or adverse 
events.  Many clinicians opt for the use of a submaximal VO2 tests because they appear 
safer than VO2peak tests.  However, multiple studies have concluded they are inaccurate 
for estimating VO2max (Dabney & Butler, 2006; De Backer et al., 2007).  Our findings 
agree with Scott et al. (2015) that a VO2peak test appears appropriate and accurate for the 
cancer population.  
In the cancer survivor group, peak Bruce heart rate was significantly lower than 
peak heart rate observed in both RMCRI protocols (RGAP and RWOGAP).  This may be 
attributed to the steep inclines observed in the BTP.  With steeper inclines, greater Type 
II muscle fibers are recruited, leading to utilization of anaerobic metabolism (Bottinelli & 
Reggiani, 2000; Boyas & Guevel, 2011; Westerblad, Bruton, & Katz, 2010).  Byproducts 
of anaerobic metabolism such as cytokines or an accumulation of phosphate may have 
led to leg pain and muscular fatigue, possibly causing the CS group to prematurely 
terminate the test before reaching their true VO2peak.  Cancer survivors may be 
experiencing cancer cachexia and detrimental muscular toxicities due to treatment, 





exertion (Berger, Gerber, & Mayer, 2012; Schneider & Hayward, 2013).  The difficult 
intensities of the BTP may have exacerbated these decrements, resulting in termination 
due to muscular fatigue and not cardiovascular fatigue.  Will et al. (1999) also observed 
difficulties achieving a target heart rate during the BTP in a general patient population.  
These researchers believed the poor performance was due to the physical inability to keep 
up with the large incremental workloads associated with stage progression.  No 
significant differences were observed in peak HR, SBP, DBP, or RPE for the apparently 
healthy group between each protocol, as seen in other studies observing VO2peak (Bader et 
al., 1999; Myers et al, 1991; Myers et al., 1992; Wall et al., 2014). 
It was hypothesized that the VO2peak achieved from BTP would be significantly 
lower than VO2peak peak obtained from RMCRI gas analysis protocol for the cancer 
survivors.  A strong positive correlation (r = 0.83) and no significant differences were 
observed between these two protocols in the AH group.  However, the CS group’s peak 
VO2 values were in fact significantly higher in BTP when compared to the RGAP, and 
only a moderate positive correlation was observed between these protocols (r = 0.51).  
The same significant observations were made when comparing the Bruce treadmill 
protocol VO2peak values against the RWOGAP.  Overestimation of VO2peak in BTP has 
been observed before, and this is in agreement with Myers et al. (1991) who suggested 
that protocols with larger increments between stages may overestimate VO2peak.  
Similarly, due to the greater magnitude of stage-based increases in exercise intensity seen 
with the BTP, a nonlinear relationship between oxygen uptake and work rate has been 
witnessed (Foster et al., 1984; Sullivan & McKirnan, 1984).  Unlike the BTP, ramp 





(Myers et al., 1991), which may explain the significant differences in VO2peak values 
between the RGAP and BTP.   
Other studies have suggested that greater work rate increments as seen in the BTP 
may result in reduced exercised capacity (Foster et al., 1984; Redwood et al., 1971; 
Sullivan & McKirman, 1984), which disagrees with the findings in this study.  However, 
equations for the Bruce protocol do not take into account an individual’s limitations, such 
as the side effects of cancer or cancer treatments.  The Bruce treadmill protocol may have 
yielded accurate values if the cancer survivors had not undergone cancer treatments.  
However, all CS received cancer-related treatments and the side effects may have 
significantly reduced the CS group’s VO2peak.  This is commonly observed following 
cancer treatments due to physical inactivity (Blanchard, Courneya, & Stein, 2008; Coups 
& Ostroff, 2004; Kim et al., 2006; Murnane et al., 2012), which may have resulted in the 
overestimation from the BTP.  The RMCRI protocol is intended to take these side effects 
into consideration using shorter and less intense stages, yielding a more accurate VO2peak 
and a subsequently lower VO2peak compared to the estimation from the BTP, which does 
not take those side effects into account.  This may also explain why the BTP VO2peak 
values did not significantly differ between any of the RMCRI protocols in the apparently 
healthy group.  Results of this study suggest the RGAP has lower but more accurate 
values than BTP, which concurs with Myers et al. (1991) who stated that smaller work 
increments may yield a more accurate relationship between oxygen demand and supply at 
high levels of exercise, but may have slightly reduced values when compared with 





The overestimation of the Bruce has important implications on the development 
of an individualized CS exercise prescription.  VO2peak is critical to have to accurately 
progress and improve cardiovascular health for a CS using exercise prescriptions 
(Heyward, 2013).  Because the BTP over predicted VO2peak, this could lead to a faulty 
exercise prescription due to the inaccurate VO2peak value.  With an over predicted value, a 
cancer survivor’s exercise prescription will be inaccurate and may result in too difficult 
intensities for a CS to sustain.  If a CS cannot tolerate the prescribed intensities from an 
exercise prescription, then no gains or progressions will be made.  Without a reliable and 
accurate exercise prescription, a CS has no guidelines or instructions to follow that are 
needed to improve the deficiencies caused by the cancer and its treatments.  The RMCRI 
protocol has been established to provide accurate VO2peak values, and therefore is a 
critical protocol to use to provide useful values for an exercise prescription.   
 VO2peak did not differ between the RMCRI gas analysis protocol and the RMCRI 
without gas analysis protocol for both the cancer survivor and apparently healthy group.  
However, total treadmill time of the RWOGAP (12.66 ± 3.01) was significantly higher 
than treadmill time from the RGAP (12.12 ± 2.82) (p < 0.05) for the CS group only.  The 
AH group also had a greater treadmill time on the RMWOGA (16.87 ± 3.96) than the 
RGAP (16.62 ± 4.31), but this was non-significant.  To our knowledge, this is the first 
study to address whether the metabolic cart, specifically the respiratory mask attached to 
the face of the participant, might hinder treadmill performance in cancer survivors.  
Anecdotally, multiple participants reported that the respiration mask was uncomfortable 
to wear and being unable to breathe normally through their noses made testing very 





them to hyperventilate in a situation that already made it problematic to breathe normally.  
The difficulties experienced by our participants using the mask were not unfounded, as 
participants have reported shortness of breath, throat irritation, and dry mouth due to the 
different types of respiratory masks and mouth guards, all of which could cause a test to 
end prematurely (Baran et al., 2001; Bart & Wolfel, 1994; Gardiner & Ranalli, 2000; 
Hurst, 2004; Yarar et al., 2013). This might also explain the lower treadmill time on the 
RGAP. 
Participants from both groups disliked how they could only look forward and not 
move their head in any other direction during the RGAP test.  AH participants stated that 
not being able to look in any direction but forward made them concentrate more on their 
balance, as they were worried about tripping.  Peripheral neuropathy and balance issues 
are a common side effect of cancer treatments (Stone et al., 2011; Wampler et al., 2007; 
Winters-Stone et al., 2011), and may be problematic for cancer survivors who are 
required to wear a piece of equipment that might aggravate this issue.  If a participant is 
concentrating on balance instead of walking and physically exerting themselves, it may 
result in a lower and less accurate VO2peak because the test was terminated due to reasons 
other than cardiovascular fatigue.  This may explain the trending towards reduced, but 
non-significant, treadmill time for the AH group using the RGAP protocol.  Even though 
VO2peak did not significantly differ between these two protocols for either group, treadmill 
time was significantly affected in the CS group, which could result in lower overall 
VO2peak values.  This further supports the notion that GA is not the ideal scenario to test a 
cancer survivor’s VO2peak, even though it is the most accurate method.  Our finding that 





not required.  Furthermore, the finding that the GA equipment may actually hinder 
performance substantiates this claim. 
Total treadmill time significantly differed between the Bruce treadmill protocol 
and both RMCRI treadmill protocols (RGAP and RWOGAP) for both the CS and AH 
groups (p < 0.001), however the RMCRI and BTP have drastically different stages.  
Because BTP consists of seven stages with each lasting three minutes and having greater 
magnitudes of changes in intensity with each stage, a participant is expected to fatigue 
earlier.  The RMCRI protocol consists of 21 one-minute stages that gradually increase the 
magnitude of intensity, allowing a participant to go further into a test, and thus longer.  
Although a significant difference in treadmill time between the two protocols exists, this 
was expected as the RMCRI protocol is specifically designed to let a participant go 
further into the protocol.  Additionally, 13% of the apparently healthy group was able to 
complete the entire RMCRI treadmill protocol, while none of the cancer survivor group 
were able to accomplish this feat.  Furthermore, none of the total participants were able to 
complete the entire BTP.  Because 13% of the AH group was able to finish the RMCRI 
protocol and not one could finish the BTP, this supports the notion that the BTP is an 
appropriate protocol for the AH population, but the RMCRI protocol may not be.  The 
RMCRI protocol was designed to increase intensity in low magnitudes to account for 
cancer treatment side effects, so an individual that has had no cancer treatments may be 
able to better sustain the protocol and go further, increasing the chance of completing the 
protocol.  The AH participants had no treatments related to cancer, allowing them to 
sustain the lower degree changes in intensity, which may explain why some were able to 





protocol, it seems fitting that this could be a treadmill protocol that is tailored specifically 
for participants suffering from cancer and cancer related treatments. 100% of the CS 
participants had received treatments related to cancer, which would explain why none of 
the CS participants could complete the protocol, yet an accurate VO2peak was still 
achieved.  The RMCRI protocol was designed for this very reason: easy to progress 
through but extremely difficult to complete for a cancer survivor suffering from cancer 
and cancer treatment side effects. 
 At the completion of all three treadmill tests, every participant was asked what 
protocol would be best for use with a cancer survivor population.  It was unanimously 
agreed upon among all of the participants that the RMCRI protocol was best suited for a 
cancer survivor.  When asked what the worst protocol for a cancer survivor to be tested 
on, 12 of the 16 participants in the apparently healthy group stated the Bruce treadmill 
protocol would be the worst, and four indicated that RGAP would be the worst.  Many of 
the AH participants stated the inclines experienced during the BTP would be too much 
for a CS to handle.  Subjects who thought the metabolic cart would be the worst protocol 
asserted the equipment attached to the face would make it unbearable for a patient.    
Limitations and Future Directions 
 There were several limitations to this study.  First, the sample size for the 
apparently healthy control group was relatively small, and a greater number of control 
subjects would have been preferred to reduce statistical error.  Second, all cancer 
survivors participants were already enrolled in the RMCRI program and had completed 
the RMCRI protocol during their initial assessment.  Although the CS participants did not 





intensity, familiarity with the protocol could have played a role.  This did not appear to 
have an effect on the results, but it should be considered for future data collection.  
Finally, participants may have performed better on the last completed protocol compared 
to the first protocol completed due to intra-rater reliability.  The participants didn’t know 
how any of the protocols progressed in intensity, but comfort to the environment and staff 
assisting with the tests may have grown over the three weeks, allowing a participant to go 
further on the last test. 
 It is possible that the RMCRI protocols were underestimating VO2peak for CS, as 
average RER was 0.9.  However, it is interesting to note that peak HR was significantly 
higher during both RMCRI protocols compared to the Bruce.  It’s plausible that CS 
resting RER was lower at rest compared to the AH group.  Because gas analysis was not 
utilized during BTP, it is impossible to tell if resting and peak RER values were as low, if 
not lower, during BTP.   
 The ACSM walking and running equations that were used to calculate EVACSM 
were meant to calculate VO2peak when an individual reached a steady state heart rate.  For 
the RMCRI protocol, steady state may not have been achieved in the one minute stages.  
However, the findings that EVACSM did not significantly differ from RGAP suggests 
that ACSM’s walking and running equations are appropriate to calculate VO2peak for the 
RMCRI protocol, despite not reaching a steady state heart rate. 
 For future research, a greater sample size for a control group is suggested.  This 
would decrease the risk of error in statistical analyses.  Also, validating the RMCRI 
protocol to other less intense protocols would be useful, such as the modified Balke, the 





Walk test.  It would be beneficial to examine differences in VO2peak values obtained from 
any of these protocols and the RMCRI protocol.  An additional method of determining 
whether a participant reaches their true VO2peak would be by taking blood lactate, which 
was not utilized in this study.  Finally, it may also be useful to familiarize the participants 
with the three different treadmill protocols before starting the study.  This way 
participants would know what to expect from each protocol, possibly allowing 
participants to go further, resulting in greater VO2peak.  Scott et al. (2015) found similar 
findings to this theory.  After prostate cancer survivors’ VO2peak was tested twice within a 
week, VO2peak was significantly higher on the second trial compared to the first trial, 
which may have been due to familiarity with the protocol. 
Conclusion 
 The present study examined the construct validity of the first cancer-specific 
treadmill VO2peak assessment, the RMCRI multi-stage treadmill protocol.  VO2peak from 
the RMCRI gas analysis protocol did not significantly differ from EVACSM, suggesting 
gas analysis is not necessary during this protocol.  Further supporting this claim, GA did 
appear to significantly decrease treadmill time, resulting in a lower VO2peak value.  The 
Bruce treadmill protocol utilizes large stage-related increases in exercise intensity which 
may be too difficult for cancer survivors to complete.  This results in inaccurate values 
which supports our findings of significantly higher VO2peak values from BTP compared to 
the RGAP test.  The RMCRI protocol was specifically designed to decrease the 
magnitude of intensity experienced with each stage, allowing cancer survivors suffering 
from cancer and treatment-related side effects to progress further into the protocol, 





the development of an accurate exercise prescription, and is the first and foremost step in 
the design of a rehabilitation program. It is proposed that cancer rehabilitation clinics and 
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Rocky Mountain Cancer Rehabilitation Institute 
Medical History 
I. General Information 
Date_______________________ 
Name_________________________________                    Age________ 
Current Primary Care Physician__________________________________ 
Current Oncologist ____________________________________________ 
Date of Last Complete Physical___________________ 
Check ALL spaces below which apply to you.  (If checked, please include explanation 
                                                                                    and date of occurrence.) 
II.  Present Medical History                              Explain and Date: 
_____Rheumatic fever/heart murmur________________________________________  
_____High blood pressure_________________________________________________  
_____Chest discomfort___________________________________________________  
_____Heart abnormalities (racing, skipping beats)______________________________     
_____Abnormal EKG____________________________________________________  
_____Heart problems_____________________________________________________  
_____Coughing up blood_________________________________________________  




_____Migraine or recurrent headaches_______________________________________  
_____Dizziness or fainting spells___________________________________________  
_____Leg pain after walking short distances__________________________________  
_____Back/neck pain/injuries______________________________________________  
_____Foot/ankle problems________________________________________________  





_____ Lung disease______________________________________________________ 
_____Respiratory problems/asthma_________________________________________ 
_____Chronic or recurrent cough___________________________________________ 









Medical History (page 2) 







_____Currently pregnant__________________________________________________  
_____Menstrual irregularities______________________________________________ 
_____Number of children_________________________________________________ 
Last mammogram:________________________ 
Last pelvic/pap:__________________________ 
Breast self exam:  Yes   No 
Operations (starting with the most recent)  
         1.____________________________________Date:__________________ 
          2.____________________________________Date:__________________ 
                     3.____________________________________Date:__________________ 
          4.____________________________________Date:__________________ 
 
Hospitalizations (reason)__________________________________________________ 
III.  Family Medical History       
_____High blood pressure    Family member(s)?________________________________  
_____Heart attacks               Family member(s)?________________________________ 
_____Heart surgery              Family member(s)?________________________________  
_____High cholesterol          Family member(s)?________________________________  
_____Stroke                          Family member(s)?________________________________ 
_____Diabetes                      Family member(s)?________________________________ 
_____Obesity                        Family member(s)?________________________________ 
_____Early death                  Family member(s)?________________________________ 
_____Cancer     Type? ______________      Family member?______________   
                          Type? ______________      Family member?______________ 









List all current medications: 
Medication:              Dosage:                   Date Started: 
1._____________________  ___________________ __________________ 
2._____________________  ___________________ __________________ 
3._____________________  ___________________ __________________ 
4._____________________  ___________________ __________________ 
5._____________________    ___________________         __________________ 
6._____________________    ___________________         __________________ 




Data Reviewed By ______________________________________________ 


































For Participation in Research at RMCRI 
Project Title: 
Exercise Interventions to Attenuate the  
Negative Side-effects of Cancer Treatments 
 
Rocky Mountain Cancer Rehabilitation Institute 
Reid Hayward, Ph.D., Director 
Phone Number:  970-351-1821 
Reid.Hayward@unco.edu 
 
Jessica Brown, M.S., Clinical Coordinator 
Phone Number:  970-351-1724 
Jessica.Brown@unco.edu 
 
The Rocky Mountain Cancer Rehabilitation Institute (RMCRI) and the School of 
Sport and Exercise Science support the practice of protection of human subjects 
participating in research.  The following information is provided for you to decide 
whether you wish to participate in either the standard RMCRI program or if recruited, 
specific research investigations.  You should be aware that even if you agree to 
participate, you are free to withdraw at any time without affecting opportunities for 
participation in other programs offered by this department. 
 This program is involved with the assessment of your body composition, 
pulmonary function, cardiovascular endurance, muscular strength and endurance, range 
of motion and flexibility. Skinfold calipers will be used to measure body composition 
(body fat percentage). The pulmonary function test will be measured through maximum 
exhalation into a sterile mouthpiece. Measuring oxygen consumption on a motor-driven 
treadmill will assess your cardiorespiratory capacity.  Assessment of muscular strength 
and endurance will occur through the use of weights, dumbbells, a handgrip 
dynamometer, and other established tests.  Flexibility and range of motion will be 
measured by an instrument called a goniometer and by the modified sit-and-reach test. 
Baseline measurements such as: heart rate, blood pressure, height, weight, and 
circumference measurements will be taken for risk stratification and safety during your 
participation.  Forms to be completed for the program include cancer history, medical 





quality of life, fatigue and cognitive functioning.  Blood may be drawn with your 
permission at various time points during your participation.   Once all of the tests are 
completed, the results will be analyzed and an exercise prescription will be written. You 
may then have the option of participating in a three month exercise intervention based on 
your testing results. The expected benefits associated with your participation in this 
program include information regarding your level of physical fitness and recommended 
fitness and lifestyle changes necessary to improve your quality of life and health.   
 If you are recruited, and agree to participate in a specific research investigation, 
additional exercise, psychological, and/or cognitive tests may be administered. Your 
optional three month exercise intervention may also differ, but the expected benefits 
should still include improved quality of life and health.  
All participants at RMCRI will be under the direction of the RMCRI Director 
and Clinical Coordinator but other persons will be associated or assist with the data 
collection.  Your participation is solicited, although strictly voluntary.  The obtained data 
may be used in reports or publications but your identity will not be associated with such 
reports.  We at RMCRI, take mental distress that may accompany health issues seriously 
and will attempt to support you with counseling referrals and information on local cancer 
support groups if this is an issue.  Our staff is required to report evidence of clear and 
imminent danger. 
 This research should not result in physical injury, however, some soreness may 
occur and some of the fitness tests can be uncomfortable.  Additionally, with the blood 
draws you may feel temporary discomfort.   The duration of the discomfort is short.  
Please give your consent with full knowledge of the nature and purpose of the 
procedures, the benefits that you may expect, and the discomforts and/or risks which may 
be encountered.  We appreciate your assistance.   
“Participation is voluntary. You may decide not to participate in this study and if 
you begin participation, you may still decide to stop and withdraw at any time. Your 
decision will be respected and will not result in loss of benefits to which you are 
otherwise entitled. Having read the above and having had an opportunity to ask any 
questions, please sign below if you would like to participate in this research. A copy of 
this form will be given to you to retain for future reference if requested. If you have any 
concerns about your selection or treatment as a research participant, please contact the 
Office of Sponsored Programs, Kepner Hall, University of Northern Colorado Greeley, 
CO  80639; 970-351-2161”. 
 
________________________________            _______________________      _______ 
Signature of Subject Agreeing to Participate  Signature of Researcher                 Date 
By signing this consent you certify you are 
at least 18 years of age.   
 
_______________________________ ___________  





































Feeling Scale (FS) 
(Hardy & Rejeski, 1989) 
 
While recovering from cancer and cancer treatments, it is common to experience good 
days, normal days, and not-so-good days.  Researchers have developed a scale to measure 
such experiences.  On the scale below, circle the number that indicates how you feel 
physically today.   
 
 
+5 Very Good 
+4  
+3  Good 
+2 
+1 Fairly good 
0 Neutral 



















ROCKY MOUNTAIN CANCER REHABILITATION  






Client Name: _____________________________        Date:__________________________ 
 
Prior to testing take resting HR, BP, and Weight 
Date of Birth:_________________     Age: ____________  RHR:  ___________   RBP:  _______________ 
 
Body Weight (lbs):)________                Kg (lbs/2.2:) ___________     Phase:________   
Max HR:___________ 
 
RMCRI Cancer Treadmill Protocol Worksheet 
Stage Speed Grade Time BP HR RPE SpO2 
0 1.0mph 0% 1 min     
1 1.5mph 0% *   
2 2.0mph 0% *   
3 2.5mph 0% *     
4 2.5mph 2% *   
5 3.0mph 2% *   
6 3.3mph 3% *     
7 3.4mph 4% *   
8 3.5mph 5% *   
9 3.6mph 6% *     
10 3.7mph 7% *   
11 3.8mph 8% *   
12 3.9mph 9% *     
13 4.0mph 10% *   
14 4.1mph 11% *   
15 4.2mph 12% *     
16 4.3mph 13% *   
17 4.4mph 14% *   
18 4.5mph 15% *     
19 4.6mph 16% *   
20 4.7mph 17% *   
Cool-Down ** 0% *     
*Identify time for each the final stage and for the cool-down        **Identify speed for cool-down  





Note: If client changes from a walk to a run during this test, identify the time when the gate 
changed. 
  
Was the client holding the handrails? Yes No 
 Was the client running during the last stage completed?  Yes  No  
 
VO2 Peak (L/Min) : ___________________  VO2 Peak (mL/kg/min) : 
_____________________ 
 























Client Name: __________________________________________  Date:_________________________ 
 Prior to testing take resting HR, BP, and Weight 
RHR:  _________________RBP:  __________________Phase: ________________ Max HR: _______________ 
 
Body Weight (lbs): _________                  Kg (lbs/2.2): _____________   DOB: __________  Age:_________ 
 
 Prior to testing, allow subject a 2–3 minute warm-up at a pace below protocol pace; explain procedures 
(purpose, BP, HR, RPE) 
 

















































































































    
 
 
*Identify time for each the final stage and for the cool-down.  **Identify speed for cool-down. 
Note: If client changes from a walk to a run during this test, identify the time when the 
gate changed. 
 
Was the client holding the handrails? Yes No 










Recovery Data (Cool-Down): 
Minute HR BP RPE  
1    
2  
3  




VO2 Peak (L/Min) : ____________             VO2 Peak (mL/kg/min) : ______________ 
 






















ACSM – American College of Sports Medicine 
AH – apparently healthy  
BP – blood pressure  
BTP – Bruce treadmill protocol  
CES – Cancer Exercise Specialist  
CHF – congestive heart failure  
CRF – cancer related fatigue 
CS – cancer survivor 
DBP – diastolic blood pressure  
DOX – doxorubicin  
EVACSM - estimated max volume of oxygen consumption using last completed stage 
of the Rocky Mountain Cancer Rehabilitation Institute gas analysis protocol  
FEV1 - forced expiratory capacity  
FRS - Framingham risk score 
FVC – force vital capacity 
GA – gas analysis 
HR – heart rate 
METS – metabolic equivalent 
O2 – oxygen 
PAR-Q – physical activity readiness questionnaire 
QOL – quality of life 
RBP – resting blood pressure 
RDBP – resting diastolic blood pressure 
RER – respiratory exchange ratio 
RGAP – Rocky Mountain Cancer Rehabilitation Institute gas analysis protocol 
RHR – resting heart rate 
RMCRI – Rocky Mountain Cancer Rehabilitation Institute 
RPE – rating of perceived exertion 
RSBP – resting systolic blood pressure 
SAS - Statistical Analysis System 
SBP – systolic blood pressure 
SPO2 - blood oxygen saturation 
SPSS - Statistical Package for the Social Sciences 
UNC – University of Northern Colorado 
VO2 – volume of oxygen consumption 
VO2peak – peak volume of oxygen consumption 
VO2max – maximum volume of oxygen consumption 
 
 
